<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nutr Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Nutr Sci</journal-id><journal-id journal-id-type="publisher-id">JNS</journal-id><journal-title-group><journal-title>Journal of Nutritional Science</journal-title></journal-title-group><issn pub-type="epub">2048-6790</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25191544</article-id><article-id pub-id-type="pmc">4153331</article-id><article-id pub-id-type="doi">10.1017/jns.2012.13</article-id><article-id pub-id-type="pii">S2048679012000134</article-id><article-id pub-id-type="publisher-id">00013</article-id><article-categories><subj-group subj-group-type="heading"><subject>Human and Clinical Nutrition</subject></subj-group></article-categories><title-group><article-title>Dietary supplementation with fish gelatine modifies nutrient intake and leads
to sex-dependent responses in TAG and C-reactive protein levels of insulin-resistant
subjects</article-title><alt-title alt-title-type="left-running">&#x000c9;. Picard-Deland <italic>et al.</italic></alt-title><alt-title alt-title-type="right-running">Fish gelatine and cardiovascular
markers</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Picard-Deland</surname><given-names>&#x000c9;liane</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lavigne</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Marois</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bisson</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Weisnagel</surname><given-names>S. John</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Marette</surname><given-names>Andr&#x000e9;</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Holub</surname><given-names>Bruce</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Chu</surname><given-names>Eugene</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Frohlich</surname><given-names>Jiri</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>John S.</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Jacques</surname><given-names>H&#x000e9;l&#x000e8;ne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Institute of Nutraceuticals and Functional
Foods</institution>, <addr-line>Quebec</addr-line>, <country>Canada</country><addr-line>G1V 0A6</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Food Science and Nutrition,
Quebec</addr-line>, <country>Canada</country><addr-line>G1V 0A6</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Medicine, Faculty of
Medicine</addr-line>, <institution>Cardiology Axis of the Institut Universitaire de
Cardiologie et de Pneumologie de Qu&#x000e9;bec (H&#x000f4;pital Laval) and Metabolism</institution>,
<addr-line>Vascular and Renal Health Axis, Quebec</addr-line>, <country>Canada</country><addr-line>G1V 4G5</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Social and Preventive Medicine,
Division of Kinesiology</addr-line>, <institution>Laval University</institution>,
<addr-line>Quebec</addr-line>, <country>Canada</country><addr-line>G1V 0A6</addr-line></aff><aff id="aff5"><label>5</label><institution>Diabetes Research Unit, Lipid Research Center,
Laval University Hospital Research Center</institution>, <addr-line>Quebec</addr-line>,
<country>Canada</country><addr-line>G1V 4G2</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Department of Human Health and Nutritional
Sciences</addr-line>, <institution>University of Guelph</institution>,
<addr-line>Guelph</addr-line>, <country>Canada</country><addr-line>N1G 2W1</addr-line></aff><aff id="aff7"><label>7</label><addr-line>UBC James Hogg Research Centre</addr-line>,
<institution>Institute for Heart and Lung Health and Department of Pathology and
Laboratory Medicine, University of British Columbia</institution>, <addr-line>Vancouver,
BC</addr-line>, <country>Canada</country><addr-line>V6Z 1Y6</addr-line></aff><author-notes><corresp id="cor1"><label>*</label><addr-line><bold>Corresponding author:</bold> H&#x000e9;l&#x000e8;ne
Jacques</addr-line>, fax <fax>+418 656 3353</fax>, email <email>helene.jacques@fsaa.ulaval.ca</email></corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>23</day><month>10</month><year>2012</year></pub-date><volume>1</volume><elocation-id>e15</elocation-id><history><date date-type="received"><day>17</day><month>10</month><year>2011</year></date><date date-type="rev-recd"><day>29</day><month>6</month><year>2012</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access"><license-p><!--CREATIVE COMMONS-->The online version of this article is published within an Open Access
environment subject to the conditions of the Creative Commons
Attribution-NonCommercial-ShareAlike licence
&#x0003c;<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/2.5/">http://creativecommons.org/licenses/by-nc-sa/2.5/</ext-link>&#x0003e;. The written
permission of Cambridge University Press must be obtained for commercial
re-use.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="S2048679012000134a.pdf"/><abstract abstract-type="normal"><p>Previous studies have shown that fish protein, as well as marine <italic>n</italic>-3
PUFA, may have beneficial effects on cardiovascular risk profile. The objectives of this
study were to investigate the combined effects of fish gelatine (FG) and
<italic>n</italic>-3 PUFA supplementation on (1) energy intake and body weight, (2) lipid
profile and (3) inflammatory and CVD markers in free-living insulin-resistant males and
females. Subjects were asked to consume, in a crossover study design with two experimental
periods of 8 weeks each, an <italic>n</italic>-3 PUFA supplement and <italic>n</italic>-3
PUFA supplement plus FG (<italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG). <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG
led to an increase in protein intake and a decrease in carbohydrate intake compared with
<italic>n</italic>-3 PUFA (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;02) in males and females.
Sex&#x02013;treatment interactions were observed for TAG (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;03) and highly
sensitive C-reactive protein (hsCRP) (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;001) levels. In females,
<italic>n</italic>-3 PUFA reduced plasma TAG by 8&#x000a0;% and <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG
by 23&#x000a0;%, whereas in males, <italic>n</italic>-3 PUFA reduced plasma TAG by 25&#x000a0;% and
<italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG by 11&#x000a0;%. <italic>n</italic>-3 PUFA increased serum hsCRP
by 13&#x000a0;% and <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG strongly reduced hsCRP by 40&#x000a0;% in males,
whereas in females, <italic>n</italic>-3 PUFA reduced serum hsCRP by 6&#x000a0;% and
<italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG increased hsCRP by 20&#x000a0;%. In conclusion, supplementation
with FG may enhance the lipid-lowering effect of marine <italic>n</italic>-3 PUFA in
females and beneficially counteract the effect of <italic>n</italic>-3 PUFA on serum hsCRP
in males. Further studies are needed to identify the sex-dependent mechanisms responsible
for the divergent effects of FG on TAG and hsCRP levels in females and males,
respectively.</p></abstract><kwd-group><title>Key words</title><kwd>Fish gelatine</kwd><kwd><italic>n</italic>-3 Fatty acids</kwd><kwd>TAG</kwd><kwd>Inflammatory markers</kwd><kwd>CVD</kwd></kwd-group><kwd-group kwd-group-type="abbreviations"><title>Abbreviations</title><kwd>FG, fish gelatine</kwd><kwd>hsCRP, highly sensitive C-reactive protein</kwd></kwd-group><counts><fig-count count="2"/><table-count count="4"/><ref-count count="49"/><page-count count="10"/></counts></article-meta></front><body><p>Over the last few decades, dyslipidaemia and chronic low-grade inflammation associated with
obesity have been described as key features of obesity-related insulin resistance, CVD and
type 2 diabetes<sup>(</sup><xref rid="ref1" ref-type="bibr">
<sup>1</sup>
</xref><sup>)</sup>.</p><p>Marine <italic>n</italic>-3 PUFA, EPA and DHA have been shown to contribute to cardiovascular
protection by their ability to induce independent and beneficial effects on lipid profile by
reducing plasma TAG and by increasing plasma HDL-cholesterol<sup>(</sup><xref rid="ref2" ref-type="bibr">
<sup>2</sup>
</xref><sup>)</sup>. Furthermore, it has been proposed that dietary <italic>n</italic>-3 PUFA
can reduce low-grade inflammatory state by modulating the eicosanoid system and the
transcription factors NF-&#x003ba;B and PPAR<sup>(</sup><xref rid="ref3" ref-type="bibr">
<sup>3</sup>
</xref><sup>)</sup>. Indeed, increasing evidence shows that the ingestion of EPA and DHA in
human subjects may reduce the secretion of pro-inflammatory cytokines, e.g. IL-6, TNF-&#x003b1;, and
monocyte chemoattractant protein-1, by adipocytes and macrophages<sup>(</sup><xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref><sup>)</sup>. However, other intervention trials have not confirmed these
effects<sup>(</sup><xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref><sup>,</sup><xref rid="ref6" ref-type="bibr">
<sup>6</sup>
</xref><sup>)</sup> and these studies using <italic>n</italic>-3 fatty acid supplementation
have failed to show any effect on the levels of systemic pro-inflammatory cytokine C-reactive
protein<sup>(</sup><xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref><sup>,</sup><xref rid="ref6" ref-type="bibr">
<sup>6</sup>
</xref><sup>)</sup> even though the fish oil supplement was given at a high
dose<sup>(</sup><xref rid="ref6" ref-type="bibr">
<sup>6</sup>
</xref><sup>)</sup>.</p><p>CVD risk factors and type 2 diabetes have also been shown to be strongly influenced by energy
intake and weight loss. Thus, the optimal macronutrient composition of a diet that facilitates
lasting and safe weight loss and that improves markers of CVD risk factors remains an area of
great controversy<sup>(</sup><xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref><sup>)</sup>. Interestingly, increasing the amount of protein may positively influence
the regulation of food intake by improving satiety and modulating energy
balance<sup>(</sup><xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref><sup>,</sup><xref rid="ref9" ref-type="bibr">
<sup>9</sup>
</xref><sup>)</sup>. Besides, there has also been interest in the effect of various types of
proteins on the modulation of CVD risk factors.</p><p>Fish protein has indeed been shown to induce beneficial effects on insulin
sensitivity<sup>(</sup><xref rid="ref10" ref-type="bibr">
<sup>10</sup>
</xref><sup>,</sup><xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref><sup>)</sup>, blood lipids<sup>(</sup><xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref><sup>&#x02013;</sup><xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref><sup>)</sup> and systemic inflammation<sup>(</sup><xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref><sup>,</sup><xref rid="ref17" ref-type="bibr">
<sup>17</sup>
</xref><sup>)</sup>. In comparison with other animal proteins, fish protein has been shown to
modulate lipid profile by decreasing VLDL TAG in pre- and post-menopausal
females<sup>(</sup><xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref><sup>,</sup><xref rid="ref13" ref-type="bibr">
<sup>13</sup>
</xref><sup>)</sup> and increasing HDL<sub>2</sub>-cholesterol in
normocholesterolaemic<sup>(</sup><xref rid="ref14" ref-type="bibr">
<sup>14</sup>
</xref><sup>)</sup> and hypercholesterolaemic males<sup>(</sup><xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref><sup>)</sup>. In addition, we<sup>(</sup><xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref><sup>)</sup> and others<sup>(</sup><xref rid="ref17" ref-type="bibr">
<sup>17</sup>
</xref><sup>)</sup> recently observed that highly sensitive C-reactive protein (hsCRP) is
reduced following a lean fish diet. The effects of fish protein on CVD risk factors have been
proposed to be due, at least in part, to its unique amino acid profile rich in glycine,
taurine and arginine. On the other hand, one of our previous studies<sup>(</sup><xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref><sup>)</sup> showed that fish protein and menhaden oil exerted additive and independent
effects on plasma TAG metabolism in the rat. In that study the combination of cod protein and
menhaden oil lowered plasma TAG by 50&#x000a0;%. In recent years, there has been growing interest in
studying the properties of fish gelatine (FG)<sup>(</sup><xref rid="ref19" ref-type="bibr">
<sup>19</sup>
</xref><sup>)</sup>, composed of peptides and amino acids resulting from collagen hydrolysis.
Indeed, there is increasing evidence for the use of collagen hydrolysate supplementation for
patients with inflammatory disease<sup>(</sup><xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref><sup>)</sup>, and it has been shown that ingestion of collagen may have hypolipidaemic
effects in animals<sup>(</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>,</sup><xref rid="ref22" ref-type="bibr">
<sup>22</sup>
</xref><sup>)</sup>. However, there is little information about the effects of FG
supplementation on lipid profile and inflammatory and CVD markers in human subjects.</p><p>Based on evidence indicating that marine <italic>n</italic>-3 PUFA and fish protein could
independently reduce CVD markers, this study was designed to compare the combined effects of a
FG and <italic>n</italic>-3 PUFA supplement with those of an <italic>n</italic>-3 PUFA
supplement on (<xref rid="ref1" ref-type="bibr">1</xref>) energy intake and body weight,
(<xref rid="ref2" ref-type="bibr">2</xref>) lipid profile and (<xref rid="ref3" ref-type="bibr">3</xref>) inflammatory and CVD markers in free-living insulin-resistant subjects.
We hypothesised that the FG supplement would reduce energy intake and body weight and improve
the effects of marine <italic>n</italic>-3 PUFA on blood lipids, cytokines and CVD indicators
in insulin-resistant males and females. As there is considerable evidence that sex hormones
may modulate food intake, body weight<sup>(</sup><xref rid="ref23" ref-type="bibr">
<sup>23</sup>
</xref><sup>)</sup> and lipid and inflammatory metabolism<sup>(</sup><xref rid="ref24" ref-type="bibr">
<sup>24</sup>
</xref><sup>)</sup>, we further explored possible sex differences in the effect of FG on those
parameters.</p><sec id="sec1"><title>Experimental methods</title><sec id="sec1-1"><title>Subjects</title><p>A total of twenty-one subjects, ten males and eleven females, aged 35&#x02013;70 years, were
recruited in the Quebec City area by media advertising. All subjects completed a medical
evaluation, including routine laboratory testing and a 75&#x000a0;g oral glucose tolerance test.
Individuals were eligible if they were overweight or obese
(BMI&#x000a0;&#x0003e;&#x000a0;25&#x000a0;kg/m<sup>2</sup>) and were insulin-resistant with high fasting plasma
insulin<sup>(</sup><xref rid="ref25" ref-type="bibr">
<sup>25</sup>
</xref><sup>)</sup> corresponding to the percentile above the 75th for fasting insulin
levels in a sample from the adult Quebec population<sup>(</sup><xref rid="ref26" ref-type="bibr">
<sup>26</sup>
</xref><sup>)</sup>, and/or had impaired fasting plasma glucose (5&#x000b7;6&#x02013;6&#x000b7;9&#x000a0;m<sc>m</sc>),
and/or had impaired glucose tolerance following 2&#x000a0;h post 75&#x000a0;g oral glucose tolerance test
with plasma glucose corresponding to 7&#x000b7;8&#x02013;11&#x000b7;0&#x000a0;m<sc>m</sc><sup>(</sup><xref rid="ref27" ref-type="bibr">
<sup>27</sup>
</xref><sup>)</sup>. Exclusion criteria included weight change&#x000a0;&#x000b1;&#x000a0;10&#x000a0;% within the 6 months
that preceded the study, major surgery in the 3 months prior to study onset, diabetes,
familial or primary hyperlipidaemia, hepatic or metabolic diseases, smoking, chronic
hypertension (&#x0003e;160/100&#x000a0;mmHg), incompatibility with fish consumption (allergy,
intolerance or dislike), and medications known to affect the lipid and glucose metabolism.</p><p>This study was conducted according to the guidelines laid down in the Declaration of
Helsinki and all procedures involving human subjects were approved by the Clinical
Research Ethical Committee of Laval University Hospital Center. After the experimental
protocol was explained with precaution, written informed consent was obtained from all
subjects.</p></sec><sec id="sec1-2"><title>Experimental design</title><p>A crossover design with two experimental periods of 8 weeks was used. After a 4-week
run-in period, either an <italic>n</italic>-3 PUFA supplement alone or an
<italic>n</italic>-3 PUFA supplement plus FG incorporated into a broth
(<italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG) was administered randomly to the subjects. At the end of
the first experimental period, participants returned to their usual diet for a washout
period of 12 weeks, including a second 4-week run-in period. Then, the participants
crossed over to the other experimental diet for an additional 8 weeks. During the 4-week
run-in periods, the participants were asked not to consume products that contained marine
<italic>n</italic>-3 PUFA, to maintain their regular food habits and their physical
activity level and to refrain from alcohol consumption (not more than one drink per d for
females and two drinks per d for males).</p></sec><sec id="sec1-3"><title>Diets</title><p>The <italic>n</italic>-3 PUFA supplement provided during the <italic>n</italic>-3 PUFA
and the <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG supplements corresponded to 1&#x000b7;8&#x000a0;g of EPA and DHA
per d in a 2:1 ratio (capsules provided by Ocean Nutrition Canada). The FG supplement
provided during the <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG treatment corresponded to approximately
25&#x000a0;% of the participant's daily protein consumption and was incorporated into a chicken
broth. A high-molecular-weight food/pharmaceutical-grade FG (Norland Products) produced
from the hydrolysis of collagen was used to prepare the FG broth. It was produced from
lean fish skins, mainly from cod, pollock and haddock. Amino acid analyses of the FG were
performed at Quebec's Aquaculture and Fisheries Innovation Centre, Quebec, using a
technique previously described by Beaulieu <italic>et al.</italic><sup>(</sup><xref rid="ref28" ref-type="bibr">
<sup>28</sup>
</xref><sup>)</sup>. Briefly, a pre-column derivatisation technique, the AccQ-Tag amino
acid analysis procedure (Waters), was used for the measurement of amino acids resistant to
acidic hydrolysis. The amino acids were separated by reversed-phase HPLC and quantified
using fluorescence detection. The amino acid composition of FG is shown in <xref ref-type="table" rid="tab01">Table 1</xref>. <table-wrap id="tab01" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Amino acid composition of fish gelatine (FG)<xref ref-type="table-fn" rid="tab-fn01">*</xref><xref ref-type="table-fn" rid="tab-fn02">&#x02020;</xref></p></caption><alternatives><graphic xlink:href="S2048679012000134_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Amino acids</th><th align="center" rowspan="1" colspan="1">FG (g/100&#x000a0;g of amino acids)&#x02021;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Aspartic acid</td><td rowspan="1" colspan="1">6&#x000b7;40</td></tr><tr><td rowspan="1" colspan="1">Serine</td><td rowspan="1" colspan="1">6&#x000b7;06</td></tr><tr><td rowspan="1" colspan="1">Glutamic acid</td><td rowspan="1" colspan="1">10&#x000b7;0</td></tr><tr><td rowspan="1" colspan="1">Glycine</td><td rowspan="1" colspan="1">21&#x000b7;5</td></tr><tr><td rowspan="1" colspan="1">Histidine</td><td rowspan="1" colspan="1">2&#x000b7;09</td></tr><tr><td rowspan="1" colspan="1">Taurine</td><td rowspan="1" colspan="1">0&#x000b7;40</td></tr><tr><td rowspan="1" colspan="1">Arginine</td><td rowspan="1" colspan="1">7&#x000b7;50</td></tr><tr><td rowspan="1" colspan="1">Threonine</td><td rowspan="1" colspan="1">2&#x000b7;66</td></tr><tr><td rowspan="1" colspan="1">Alanine</td><td rowspan="1" colspan="1">8&#x000b7;57</td></tr><tr><td rowspan="1" colspan="1">Proline</td><td rowspan="1" colspan="1">9&#x000b7;90</td></tr><tr><td rowspan="1" colspan="1">Cysteine</td><td rowspan="1" colspan="1">0&#x000b7;67</td></tr><tr><td rowspan="1" colspan="1">Tyrosine</td><td rowspan="1" colspan="1">0&#x000b7;71</td></tr><tr><td rowspan="1" colspan="1">Valine</td><td rowspan="1" colspan="1">1&#x000b7;68</td></tr><tr><td rowspan="1" colspan="1">Methionine</td><td rowspan="1" colspan="1">1&#x000b7;93</td></tr><tr><td rowspan="1" colspan="1">Lysine</td><td rowspan="1" colspan="1">3&#x000b7;91</td></tr><tr><td rowspan="1" colspan="1">Isoleucine</td><td rowspan="1" colspan="1">1&#x000b7;01</td></tr><tr><td rowspan="1" colspan="1">Leucine</td><td rowspan="1" colspan="1">2&#x000b7;20</td></tr><tr><td rowspan="1" colspan="1">Phenylalanine</td><td rowspan="1" colspan="1">1&#x000b7;84</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tab-fn01"><label>*</label><p>Provided by Norland Products Inc. (Kenney and Ross Limited).</p></fn><fn id="tab-fn02"><label>&#x02020;</label><p>Amino acid measurements were carried out at Quebec's Aquaculture and Fisheries
Innovation Centre, Quebec, using the technique previously described by Beaulieu
<italic>et al.</italic><sup>(</sup><xref rid="ref28" ref-type="bibr">
<sup>28</sup>
</xref><sup>)</sup>.</p></fn><fn><p>&#x02021; Values are the means of two determinations.</p></fn></table-wrap-foot></table-wrap></p><p>The FG broth was prepared at the metabolic kitchen of the Institute of Nutraceuticals and
Functional Foods of Laval University and was provided daily to the subjects. The FG broth
was consumed in different recipes at home by the participants. Compliance was assessed
from the return of capsules and containers and uneaten FG broth to determine the quantity
consumed, from 24&#x000a0;h recalls every 2 weeks and from a FFQ administrated by a dietitian, at
the beginning and at the end of each experimental period. The energy and nutrient intake
information derived from compilation of the FFQ was analysed using nutrient composition
values from the Nutrition Data System for Research software version 4.03 (University of
Minnesota, Minneapolis, MN, Food and Nutrient Database, 2000). Moreover, participants were
asked to fill in a 3-d diary (two weekdays and one weekend day) during each experimental
period. All participants consumed more than 80&#x000a0;% of the FG broth and more than 85&#x000a0;% of the
<italic>n</italic>-3 PUFA supplements. The compliance for FG and <italic>n</italic>-3
PUFA supplements was more than 95&#x000a0;% for fourteen subjects.</p></sec></sec><sec id="sec2"><title>Clinical and laboratory measurements</title><sec id="sec2-1"><title>Anthropometric measurements</title><p>Height was measured with a stadiometer at the beginning of the study. Before and after
each treatment, waist circumference and hip circumference were measured in duplicate.
Waist circumference was measured at the level midway between the lowest rib margin and the
iliac crest, and hip circumference was measured at the broadest circumference below the
waist. Weight was recorded at the beginning and at the end of the two experimental
periods, and at mid-period during each experimental period using a digital scale while
subjects were barefoot. BMI was calculated as weight (in kg) divided by height (in metres)
squared.</p></sec><sec id="sec2-2"><title>Blood collection</title><p>Blood samples were drawn after a 12&#x000a0;h overnight fast from an antecubital vein, before and
after each experimental treatment. Blood samples were centrifuged immediately at 3000 <bold><italic>g</italic></bold> for 10&#x000a0;min at 4&#x000b0;C to separate plasma and serum, which were stored at &#x02212;80&#x000b0;C until
further measurements of inflammatory marker and lipid concentrations.</p></sec><sec id="sec2-3"><title>Inflammatory and cardiovascular marker concentrations</title><p>Inflammatory and cardiovascular marker concentrations were measured in serum, at the
Laval University Hospital Center, Quebec, using commercially available methods as follows:
the immunoassay Luminex xMAP Multiplexing (Millipore) was used to measure IL-6, monocyte
chemotactic protein-1, TNF-&#x003b1;, adiponectin and myeloperoxidase. IL-1&#x003b2; (Invitrogen) and IL-1
receptor antagonist (Invitrogen) were measured using an ultrasensitive ELISA kit. IL-10
(Invitrogen), serum amyloid A (Invitrogen) and asymmetric dimethylarginine (ALPCO) were
measured using an ELISA kit.</p><p>Other biomarker concentrations were measured at the Atherosclerosis Specialty Laboratory
at St Paul's Hospital, Vancouver, using commercially available methods as follows: leptin
(R&#x00026;D Systems) was measured using an ELISA kit in serum. Plasminogen activator
inhibitor-1 (R&#x00026;D Systems) and resistin (R&#x00026;D Systems) were measured using
ELISA kits in plasma. hsCRP was measured in serum using the CardioPhase hsCRP
immunonephelometry technique (Siemens Healthcare Diagnostics Products). Homocysteine was
measured in plasma using an ADVIA Centor HCY assay (Bayer Healthcare LLC), based on a
competitive immunoassay and direct chemiluminescent technique.</p></sec><sec id="sec2-4"><title>Plasma lipid and lipoprotein concentrations</title><p>Plasma VLDL (&#x0003c;1&#x000b7;006&#x000a0;g/ml) were removed from plasma using a ultracentrifugation
technique as previously reported by Moorjani <italic>et al.</italic><sup>(</sup><xref rid="ref29" ref-type="bibr">
<sup>29</sup>
</xref><sup>)</sup>. LDL was precipitated with heparin and MnCl<sub>2</sub> and HDL
particles were isolated from the bottom fraction (&#x0003e;1&#x000b7;006&#x000a0;g/ml)<sup>(</sup><xref rid="ref30" ref-type="bibr">
<sup>30</sup>
</xref><sup>)</sup><sub>.</sub> Cholesterol and TAG concentrations were determined
enzymatically by using a Technicon RA-500 analyzer (Bayer).</p></sec><sec id="sec2-5"><title>Statistical analyses</title><p>The <italic>a posteriori</italic> power of the study was calculated using the collected
data from this study. On the basis of those data, the present study had a power of 0&#x000b7;73 to
detect a 20&#x000a0;% decrease in our main outcome plasma TAG (at a two-sided &#x003b1;-level of 0&#x000b7;05) in
our fifteen subjects. Statistical analysis was performed using SAS, version 9.0 (SAS
Institute, Inc.). Differences in baseline characteristics between males and females were
assessed by the Student's <italic>t</italic> test. The PROC MIXED procedure for an ANOVA
for crossover design with two periods was used to compare the effects of the two
treatments. A statistically significant level of <italic>P</italic>&#x000a0;&#x02264;&#x000a0;0&#x000b7;05 was applied for
all tests and the results presented are means with their standard errors. The influence of
body weight, BMI, sex, and waist and hip circumferences on the changes in various
metabolic parameters measured in this study was tested by individual entry of terms and
interaction terms into the ANOVA model. No residual effects of the first experimental
period over the second period were observed for all inflammatory, cardiovascular and lipid
markers. Variable serum amyloid A was not normally distributed, so a non-parametric test
using a rank transformation was used<sup>(</sup><xref rid="ref31" ref-type="bibr">
<sup>31</sup>
</xref><sup>)</sup>.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3-1" sec-type="subjects"><title>Subjects</title><p>A total of twenty-one insulin-resistant subjects completed the study. Of these, five
subjects were excluded from the analysis because they became diabetic during the study,
according to the American Diabetes Association criteria<sup>(</sup><xref rid="ref27" ref-type="bibr">
<sup>27</sup>
</xref><sup>)</sup> and, in addition, one female was pre-menopausal and was excluded from
the analysis. The characteristics at baseline for the fifteen insulin-resistant subjects
(seven male and eight female) are reported in <xref ref-type="table" rid="tab02">Table
2</xref>. No significant differences were observed between males and females in all mean
initial characteristics excepted for HDL-cholesterol (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;01). All
subjects were overweight or obese (BMI 26&#x02013;39&#x000a0;kg/m<sup>2</sup>), fourteen subjects (eight
female and six male) had abdominal adiposity (waist circumference &#x0003e;94&#x000a0;cm for males
and &#x0003e;80&#x000a0;cm for females)<sup>(</sup><xref rid="ref32" ref-type="bibr">
<sup>32</sup>
</xref><sup>)</sup> and twelve subjects (75&#x000a0;%) met the National Heart, Lung, and Blood
Institute/American Heart Association criteria for the metabolic syndrome<sup>(</sup><xref rid="ref33" ref-type="bibr">
<sup>33</sup>
</xref><sup>)</sup>. According to the criteria for CVD risk of the Centers for Disease
Control and Prevention and the American Heart Association<sup>(</sup><xref rid="ref34" ref-type="bibr">
<sup>34</sup>
</xref><sup>)</sup>, five subjects (four male, one female) had baseline hsCRP
concentrations &#x0003c;1&#x000b7;0&#x000a0;mg/l (low risk), six (three male, three female) had
concentrations between 1 and 3&#x000a0;mg/l (moderate risk) and four females had concentrations
&#x02265;3&#x000b7;0&#x000a0;mg/l (high risk). Moreover, seven subjects (three male, four female) had optimal
fasting TAG concentrations (&#x0003c;1&#x000b7;13&#x000a0;m<sc>m</sc>), four subjects (two male, two
female) had desirable TAG concentrations (between 1&#x000b7;13 and 1&#x000b7;69&#x000a0;m<sc>m</sc>) and four
subjects (two male, two female) had normal concentrations (between 1&#x000b7;7 and
2&#x000b7;26&#x000a0;m<sc>m</sc>)<sup>(</sup><xref rid="ref35" ref-type="bibr">
<sup>35</sup>
</xref><sup>)</sup>. Baseline LDL-cholesterol concentrations were optimal
(&#x0003c;2&#x000b7;6&#x000a0;m<sc>m</sc>) for one subject (one male), near or above optimal
(2&#x000b7;6&#x02013;3&#x000b7;3&#x000a0;m<sc>m</sc>) for five (four male, one female), borderline high
(3&#x000b7;4&#x02013;4&#x000b7;1&#x000a0;m<sc>m</sc>) for four females, high (4&#x000b7;15&#x02013;4&#x000b7;9&#x000a0;m<sc>m</sc>) for three (one male,
two female) and very high (&#x02265;4&#x000b7;9&#x000a0;m<sc>m</sc>) for two (one male, one
female)<sup>(</sup><xref rid="ref36" ref-type="bibr">
<sup>36</sup>
</xref><sup>)</sup>. <table-wrap id="tab02" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Subject characteristics at baseline</p><p>(Mean values with their standard errors)</p></caption><alternatives><graphic xlink:href="S2048679012000134_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">All (<italic>n</italic> 15)</th><th align="center" colspan="2" rowspan="1">Male (<italic>n</italic> 7)</th><th align="center" colspan="2" rowspan="1">Female (<italic>n</italic> 8)</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">57&#x000b7;6</td><td rowspan="1" colspan="1">2&#x000b7;3</td><td rowspan="1" colspan="1">54&#x000b7;1</td><td rowspan="1" colspan="1">2&#x000b7;9</td><td rowspan="1" colspan="1">61&#x000b7;0</td><td rowspan="1" colspan="1">3&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">Body weight (kg)</td><td rowspan="1" colspan="1">80&#x000b7;8</td><td rowspan="1" colspan="1">2&#x000b7;6</td><td rowspan="1" colspan="1">83&#x000b7;9</td><td rowspan="1" colspan="1">4&#x000b7;0</td><td rowspan="1" colspan="1">78&#x000b7;1</td><td rowspan="1" colspan="1">3&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">29&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">28&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">30&#x000b7;9</td><td rowspan="1" colspan="1">1&#x000b7;5</td></tr><tr><td rowspan="1" colspan="1">Waist circumference (cm)</td><td rowspan="1" colspan="1">99&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;9</td><td rowspan="1" colspan="1">99&#x000b7;3</td><td rowspan="1" colspan="1">3&#x000b7;4</td><td rowspan="1" colspan="1">99&#x000b7;9</td><td rowspan="1" colspan="1">2&#x000b7;3</td></tr><tr><td rowspan="1" colspan="1">Hip circumference (cm)</td><td rowspan="1" colspan="1">108</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">104</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">112</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Cholesterol (m<sc>m</sc>)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">5&#x000b7;60</td><td rowspan="1" colspan="1">0&#x000b7;31</td><td rowspan="1" colspan="1">5&#x000b7;26</td><td rowspan="1" colspan="1">1&#x000b7;44</td><td rowspan="1" colspan="1">5&#x000b7;89</td><td rowspan="1" colspan="1">0&#x000b7;34</td></tr><tr><td rowspan="1" colspan="1">LDL</td><td rowspan="1" colspan="1">3&#x000b7;74</td><td rowspan="1" colspan="1">0&#x000b7;26</td><td rowspan="1" colspan="1">3&#x000b7;52</td><td rowspan="1" colspan="1">1&#x000b7;28</td><td rowspan="1" colspan="1">3&#x000b7;93</td><td rowspan="1" colspan="1">0&#x000b7;27</td></tr><tr><td rowspan="1" colspan="1">HDL</td><td rowspan="1" colspan="1">1&#x000b7;26</td><td rowspan="1" colspan="1">0&#x000b7;05</td><td rowspan="1" colspan="1">1&#x000b7;14</td><td rowspan="1" colspan="1">0&#x000b7;18</td><td rowspan="1" colspan="1">1&#x000b7;37</td><td rowspan="1" colspan="1">0&#x000b7;04*</td></tr><tr><td rowspan="1" colspan="1">Total TAG (m<sc>m</sc>)</td><td rowspan="1" colspan="1">1&#x000b7;29</td><td rowspan="1" colspan="1">0&#x000b7;11</td><td rowspan="1" colspan="1">1&#x000b7;29</td><td rowspan="1" colspan="1">0&#x000b7;46</td><td rowspan="1" colspan="1">1&#x000b7;29</td><td rowspan="1" colspan="1">0&#x000b7;16</td></tr><tr><td rowspan="1" colspan="1">Total cholesterol:HDL-cholesterol ratio</td><td rowspan="1" colspan="1">4&#x000b7;52</td><td rowspan="1" colspan="1">0&#x000b7;34</td><td rowspan="1" colspan="1">4&#x000b7;75</td><td rowspan="1" colspan="1">1&#x000b7;85</td><td rowspan="1" colspan="1">4&#x000b7;31</td><td rowspan="1" colspan="1">0&#x000b7;24</td></tr><tr><td rowspan="1" colspan="1">Fasting plasma glucose (m<sc>m</sc>)</td><td rowspan="1" colspan="1">6&#x000b7;07</td><td rowspan="1" colspan="1">0&#x000b7;11</td><td rowspan="1" colspan="1">5&#x000b7;98</td><td rowspan="1" colspan="1">0&#x000b7;12</td><td rowspan="1" colspan="1">6&#x000b7;14</td><td rowspan="1" colspan="1">0&#x000b7;18</td></tr><tr><td rowspan="1" colspan="1">2&#x000a0;h plasma glucose (m<sc>m</sc>)</td><td rowspan="1" colspan="1">7&#x000b7;65</td><td rowspan="1" colspan="1">0&#x000b7;45</td><td rowspan="1" colspan="1">8&#x000b7;07</td><td rowspan="1" colspan="1">0&#x000b7;88</td><td rowspan="1" colspan="1">7&#x000b7;29</td><td rowspan="1" colspan="1">0&#x000b7;37</td></tr><tr><td rowspan="1" colspan="1">Fasting plasma insulin (pmol/l)</td><td rowspan="1" colspan="1">87&#x000b7;9</td><td rowspan="1" colspan="1">17&#x000b7;8</td><td rowspan="1" colspan="1">107&#x000b7;0</td><td rowspan="1" colspan="1">33&#x000b7;0</td><td rowspan="1" colspan="1">69&#x000b7;1</td><td rowspan="1" colspan="1">12&#x000b7;9</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>* Difference between males and females, <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;01.</p></fn></table-wrap-foot></table-wrap></p><p>Our subjects were all insulin-resistant. However, among them, ten subjects had
hyperinsulinaemia (fasting plasma insulin &#x0003e;90&#x000a0;pmol/l)<sup>(</sup><xref rid="ref26" ref-type="bibr">
<sup>26</sup>
</xref><sup>)</sup>. According to the American Diabetic Association for the Diagnosis and
Classification of Diabetes Mellitus<sup>(</sup><xref rid="ref27" ref-type="bibr">
<sup>27</sup>
</xref><sup>)</sup>, two subjects (one male and one female) had normal glucose tolerance,
eight (four male and four female) had impaired fasting glucose (5&#x000b7;6&#x02013;6&#x000b7;9&#x000a0;m<sc>m</sc>) and
five (two male and three female) had both impaired fasting glucose and impaired glucose
tolerance (7&#x000b7;8&#x02013;11&#x000b7;0&#x000a0;m<sc>m</sc>: 2&#x000a0;h post 75&#x000a0;g oral glucose tolerance test).</p></sec><sec id="sec3-2"><title>Anthropometric measures</title><p>Changes in body weight (0&#x000b7;23 (<sc>sem</sc> 0&#x000b7;39)&#x000a0;kg) for <italic>n</italic>-3 PUFA and
&#x02212;0&#x000b7;02 (<sc>sem</sc> 0&#x000b7;32)&#x000a0;kg) for <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG), BMI (0&#x000b7;07 (<sc>sem</sc>
0&#x000b7;14)&#x000a0;kg/m<sup>2</sup> for <italic>n</italic>-3 PUFA and 0&#x000b7;01 (<sc>sem</sc>
0&#x000b7;11)&#x000a0;kg/m<sup>2</sup> for <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG), waist circumference (0&#x000b7;03
(<sc>sem</sc> 0&#x000b7;22)&#x000a0;cm for <italic>n</italic>-3 PUFA and 0&#x000b7;47 (<sc>sem</sc> 0&#x000b7;36)&#x000a0;cm for
<italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG) and hip circumference (&#x02212;0&#x000b7;07 (<sc>sem</sc> 0&#x000b7;4)&#x000a0;cm for
<italic>n</italic>-3 PUFA and &#x02212;0&#x000b7;03 (<sc>sem</sc> 0&#x000b7;21) cm for <italic>n</italic>-3
PUFA&#x000a0;+&#x000a0;FG) did not differ significantly between the periods.</p></sec><sec id="sec3-3"><title>Macronutrient intake</title><p>As shown in <xref ref-type="table" rid="tab03">Table 3</xref>, <italic>n</italic>-3
PUFA&#x000a0;+&#x000a0;FG led to an increase in protein intake in males (21&#x000a0;%; <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;02)
and females (12&#x000a0;%; <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;03) and a decrease in carbohydrate intake in
males (&#x02212;14&#x000a0;%; <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;01) and females (&#x02212;13&#x000a0;%; <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;05)
compared with the <italic>n</italic>-3 PUFA supplement. However, lipid and energy intakes
did not differ during the experimentation, and no differences between the treatments were
observed for these variables. <table-wrap id="tab03" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Daily dietary macronutrient intakes of males and females throughout the
experimental periods</p><p>(Mean values with their standard errors)</p></caption><alternatives><graphic xlink:href="S2048679012000134_tab3"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="9" rowspan="1">Male (<italic>n</italic> 7)</th><th align="center" colspan="8" rowspan="1">Female (<italic>n</italic> 8)</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1"><italic>n</italic>-3 PUFA</th><th align="center" colspan="4" rowspan="1"><italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG</th><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1"><italic>n</italic>-3 PUFA</th><th align="center" colspan="4" rowspan="1"><italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Pre</th><th align="center" colspan="2" rowspan="1">Post</th><th align="center" colspan="2" rowspan="1">Pre</th><th align="center" colspan="2" rowspan="1">Post</th><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Pre</th><th align="center" colspan="2" rowspan="1">Post</th><th align="center" colspan="2" rowspan="1">Pre</th><th align="center" colspan="2" rowspan="1">Post</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1">Nutrient intakes</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">
<sc>sem</sc>
</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">
<sc>sem</sc>
</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">
<sc>sem</sc>
</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value*</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">
<sc>sem</sc>
</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">
<sc>sem</sc>
</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">
<sc>sem</sc>
</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1"><italic>p</italic>*</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total energy (kJ)</td><td rowspan="1" colspan="1">10137</td><td rowspan="1" colspan="1">1527</td><td rowspan="1" colspan="1">9159</td><td rowspan="1" colspan="1">1490</td><td rowspan="1" colspan="1">9678</td><td rowspan="1" colspan="1">1406</td><td rowspan="1" colspan="1">10514</td><td rowspan="1" colspan="1">1251</td><td rowspan="1" colspan="1">0&#x000b7;39</td><td rowspan="1" colspan="1">8204</td><td rowspan="1" colspan="1">597</td><td rowspan="1" colspan="1">8679</td><td rowspan="1" colspan="1">458</td><td rowspan="1" colspan="1">7836</td><td rowspan="1" colspan="1">684</td><td rowspan="1" colspan="1">8747</td><td rowspan="1" colspan="1">621</td><td rowspan="1" colspan="1">0&#x000b7;42</td></tr><tr><td rowspan="1" colspan="1">Protein (% en)</td><td rowspan="1" colspan="1">15&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;1</td><td rowspan="1" colspan="1">15&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">15&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">19&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">17&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;1</td><td rowspan="1" colspan="1">16&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">17&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">19&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;03</td></tr><tr><td rowspan="1" colspan="1">Carbohydrates (% en)</td><td rowspan="1" colspan="1">48&#x000b7;7</td><td rowspan="1" colspan="1">2&#x000b7;7</td><td rowspan="1" colspan="1">48&#x000b7;7</td><td rowspan="1" colspan="1">1&#x000b7;5</td><td rowspan="1" colspan="1">49&#x000b7;1</td><td rowspan="1" colspan="1">1&#x000b7;9</td><td rowspan="1" colspan="1">42&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">47&#x000b7;2</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">47&#x000b7;1</td><td rowspan="1" colspan="1">1&#x000b7;7</td><td rowspan="1" colspan="1">50&#x000b7;6</td><td rowspan="1" colspan="1">2&#x000b7;2</td><td rowspan="1" colspan="1">44&#x000b7;1</td><td rowspan="1" colspan="1">2&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;05</td></tr><tr><td rowspan="1" colspan="1">Lipid (% en)</td><td rowspan="1" colspan="1">36&#x000b7;7</td><td rowspan="1" colspan="1">2&#x000b7;6</td><td rowspan="1" colspan="1">36&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;6</td><td rowspan="1" colspan="1">35&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;6</td><td rowspan="1" colspan="1">39&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;19</td><td rowspan="1" colspan="1">35&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;7</td><td rowspan="1" colspan="1">37&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;5</td><td rowspan="1" colspan="1">33&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;9</td><td rowspan="1" colspan="1">37&#x000b7;5</td><td rowspan="1" colspan="1">2&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;28</td></tr><tr><td rowspan="1" colspan="1">SFA</td><td rowspan="1" colspan="1">33&#x000b7;1</td><td rowspan="1" colspan="1">6&#x000b7;5</td><td rowspan="1" colspan="1">28&#x000b7;3</td><td rowspan="1" colspan="1">5&#x000b7;5</td><td rowspan="1" colspan="1">32&#x000b7;4</td><td rowspan="1" colspan="1">6&#x000b7;0</td><td rowspan="1" colspan="1">34&#x000b7;6</td><td rowspan="1" colspan="1">4&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;16</td><td rowspan="1" colspan="1">28&#x000b7;1</td><td rowspan="1" colspan="1">4&#x000b7;2</td><td rowspan="1" colspan="1">30&#x000b7;5</td><td rowspan="1" colspan="1">3&#x000b7;9</td><td rowspan="1" colspan="1">25&#x000b7;6</td><td rowspan="1" colspan="1">3&#x000b7;6</td><td rowspan="1" colspan="1">30&#x000b7;4</td><td rowspan="1" colspan="1">3&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;58</td></tr><tr><td rowspan="1" colspan="1">MUFA</td><td rowspan="1" colspan="1">40&#x000b7;6</td><td rowspan="1" colspan="1">6&#x000b7;8</td><td rowspan="1" colspan="1">38&#x000b7;7</td><td rowspan="1" colspan="1">8&#x000b7;4</td><td rowspan="1" colspan="1">43&#x000b7;4</td><td rowspan="1" colspan="1">5&#x000b7;7</td><td rowspan="1" colspan="1">47&#x000b7;8</td><td rowspan="1" colspan="1">5&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;39</td><td rowspan="1" colspan="1">31&#x000b7;7</td><td rowspan="1" colspan="1">3&#x000b7;6</td><td rowspan="1" colspan="1">34&#x000b7;3</td><td rowspan="1" colspan="1">2&#x000b7;7</td><td rowspan="1" colspan="1">27&#x000b7;6</td><td rowspan="1" colspan="1">3&#x000b7;6</td><td rowspan="1" colspan="1">35&#x000b7;6</td><td rowspan="1" colspan="1">4&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;12</td></tr><tr><td rowspan="1" colspan="1">PUFA</td><td rowspan="1" colspan="1">17&#x000b7;6</td><td rowspan="1" colspan="1">3&#x000b7;1</td><td rowspan="1" colspan="1">17&#x000b7;5</td><td rowspan="1" colspan="1">3&#x000b7;8</td><td rowspan="1" colspan="1">17&#x000b7;1</td><td rowspan="1" colspan="1">2&#x000b7;0</td><td rowspan="1" colspan="1">18&#x000b7;5</td><td rowspan="1" colspan="1">2&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;72</td><td rowspan="1" colspan="1">13&#x000b7;1</td><td rowspan="1" colspan="1">1&#x000b7;6</td><td rowspan="1" colspan="1">15&#x000b7;2</td><td rowspan="1" colspan="1">1&#x000b7;1</td><td rowspan="1" colspan="1">12&#x000b7;1</td><td rowspan="1" colspan="1">1&#x000b7;9</td><td rowspan="1" colspan="1">15&#x000b7;5</td><td rowspan="1" colspan="1">2&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;68</td></tr><tr><td rowspan="1" colspan="1">Fibre (g)</td><td rowspan="1" colspan="1">25&#x000b7;7</td><td rowspan="1" colspan="1">4&#x000b7;0</td><td rowspan="1" colspan="1">20&#x000b7;9</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">25&#x000b7;1</td><td rowspan="1" colspan="1">2&#x000b7;1</td><td rowspan="1" colspan="1">22&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;70</td><td rowspan="1" colspan="1">21&#x000b7;0</td><td rowspan="1" colspan="1">1&#x000b7;7</td><td rowspan="1" colspan="1">22&#x000b7;0</td><td rowspan="1" colspan="1">1&#x000b7;9</td><td rowspan="1" colspan="1">21&#x000b7;1</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">22&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;76</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>FG, fish gelatine; en, energy.</p></fn><fn><p>* <italic>P</italic> values refer to comparisons between changes induced by the
<italic>n</italic>-3 PUFA and <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG treatments (ANOVA
for crossover design with two periods).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3-4"><title>Plasma lipid concentrations, and inflammatory and CVD markers</title><p>The plasma lipid concentrations as well as the inflammatory and CVD markers of the
subjects are presented in <xref ref-type="table" rid="tab04">Table 4</xref>. When all
subjects were taken together, there were no differences in the observed changes for all
lipid and lipoprotein markers between the <italic>n</italic>-3 PUFA and
<italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG supplements. Because a sex&#x02013;treatment interaction was
observed on plasma TAG concentrations (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;03), we further analysed
those lipid data in males and females. In males (<xref ref-type="fig" rid="fig01">Fig.
1(a)</xref>), 25 and 11&#x000a0;% decreases were observed in TAG concentrations following
<italic>n</italic>-3 PUFA (1&#x000b7;63 (<sc>sem</sc> 0&#x000b7;24)&#x02013;1&#x000b7;22 (<sc>sem</sc> 0&#x000b7;18)&#x000a0;
m<sc>m</sc>) and <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG (1&#x000b7;51 (<sc>sem</sc> 0&#x000b7;29)&#x02013;1&#x000b7;34
(<sc>sem</sc> 0&#x000b7;29)&#x000a0;m<sc>m</sc>), respectively. However, no difference was observed
between changes induced by the two treatments (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;14). In females
(<xref ref-type="fig" rid="fig01">Fig. 1(b)</xref>), an 8&#x000a0;% reduction in TAG was
observed after <italic>n</italic>-3 PUFA (1&#x000b7;36 (<sc>sem</sc> 0&#x000b7;11)&#x02013;1&#x000b7;25 (<sc>sem</sc>
0&#x000b7;11)&#x000a0;m<sc>m</sc>), whereas a 23&#x000a0;% reduction was observed after <italic>n</italic>-3
PUFA&#x000a0;+&#x000a0;FG (1&#x000b7;49 (<sc>sem</sc> 0&#x000b7;13)&#x02013;1&#x000b7;15 (<sc>sem</sc> 0&#x000b7;12)&#x000a0;m<sc>m</sc>), inducing a
difference in the changes of TAG between the <italic>n</italic>-3 PUFA and
<italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG supplements (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;04). <fig id="fig01" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Plasma TAG concentrations before (pre) and after (post) consuming
<italic>n</italic>-3 PUFA and <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;fish gelatine (FG) (a) in
males and (b) in females for 8 weeks. Values are means, with standard errors
represented by vertical bars, <italic>n</italic> 7 for males, and <italic>n</italic>
8 for females. <italic>P</italic> value for sex&#x02013;treatment interaction&#x000a0;=&#x000a0;0&#x000b7;03.
<italic>P</italic> value is 0&#x000b7;04 between changes induced by the
<italic>n</italic>-3 PUFA and <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG supplements in females
(ANOVA for crossover design with two experimental periods).</p></caption><graphic xlink:href="S2048679012000134_fig1"/></fig>
<table-wrap id="tab04" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Concentrations of blood lipids, inflammatory and CVD markers before (pre) and after
(post) consuming <italic>n</italic>-3 PUFA and <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;fish
gelatine (FG) for 8 weeks in insulin-resistant males and females<xref ref-type="table-fn" rid="tab-fn08">*</xref></p><p>(Mean values with their standard errors)</p></caption><alternatives><graphic xlink:href="S2048679012000134_tab4"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="6" rowspan="1"><italic>n</italic>-3 PUFA
(<italic>n</italic> 15)</th><th align="center" colspan="6" rowspan="1"><italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG
(<italic>n</italic> 15)</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Pre</th><th align="center" colspan="2" rowspan="1">Post</th><th align="center" colspan="2" rowspan="1">&#x02206;</th><th align="center" colspan="2" rowspan="1">Pre</th><th align="center" colspan="2" rowspan="1">Post</th><th align="center" colspan="2" rowspan="1">&#x02206;</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02020;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Blood lipids (m<sc>m</sc>)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Total cholesterol</td><td rowspan="1" colspan="1">5&#x000b7;78</td><td rowspan="1" colspan="1">0&#x000b7;34</td><td rowspan="1" colspan="1">5&#x000b7;55</td><td rowspan="1" colspan="1">0&#x000b7;28</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;23</td><td rowspan="1" colspan="1">0&#x000b7;12</td><td rowspan="1" colspan="1">5&#x000b7;45</td><td rowspan="1" colspan="1">0&#x000b7;28</td><td rowspan="1" colspan="1">5&#x000b7;41</td><td rowspan="1" colspan="1">0&#x000b7;30</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;04</td><td rowspan="1" colspan="1">0&#x000b7;10</td><td rowspan="1" colspan="1">0&#x000b7;22</td></tr><tr><td rowspan="1" colspan="1">TAG</td><td rowspan="1" colspan="1">1&#x000b7;49</td><td rowspan="1" colspan="1">0&#x000b7;13</td><td rowspan="1" colspan="1">1&#x000b7;23</td><td rowspan="1" colspan="1">0&#x000b7;10</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;26</td><td rowspan="1" colspan="1">0&#x000b7;10</td><td rowspan="1" colspan="1">1&#x000b7;50</td><td rowspan="1" colspan="1">0&#x000b7;15</td><td rowspan="1" colspan="1">1&#x000b7;24</td><td rowspan="1" colspan="1">0&#x000b7;13</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;26</td><td rowspan="1" colspan="1">0&#x000b7;10</td><td rowspan="1" colspan="1">0&#x000b7;98</td></tr><tr><td rowspan="1" colspan="1">HDL-cholesterol</td><td rowspan="1" colspan="1">1&#x000b7;07</td><td rowspan="1" colspan="1">0&#x000b7;04</td><td rowspan="1" colspan="1">1&#x000b7;12</td><td rowspan="1" colspan="1">0&#x000b7;05</td><td rowspan="1" colspan="1">0&#x000b7;05</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">1&#x000b7;03</td><td rowspan="1" colspan="1">0&#x000b7;05</td><td rowspan="1" colspan="1">1&#x000b7;13</td><td rowspan="1" colspan="1">0&#x000b7;06</td><td rowspan="1" colspan="1">0&#x000b7;09</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">0&#x000b7;18</td></tr><tr><td rowspan="1" colspan="1">LDL-cholesterol</td><td rowspan="1" colspan="1">4&#x000b7;03</td><td rowspan="1" colspan="1">0&#x000b7;30</td><td rowspan="1" colspan="1">3&#x000b7;87</td><td rowspan="1" colspan="1">0&#x000b7;26</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;16</td><td rowspan="1" colspan="1">0&#x000b7;08</td><td rowspan="1" colspan="1">3&#x000b7;73</td><td rowspan="1" colspan="1">0&#x000b7;23</td><td rowspan="1" colspan="1">3&#x000b7;72</td><td rowspan="1" colspan="1">0&#x000b7;26</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;02</td><td rowspan="1" colspan="1">0&#x000b7;09</td><td rowspan="1" colspan="1">0&#x000b7;22</td></tr><tr><td rowspan="1" colspan="1">Total cholesterol:HDL-cholesterol ratio</td><td rowspan="1" colspan="1">5&#x000b7;54</td><td rowspan="1" colspan="1">0&#x000b7;47</td><td rowspan="1" colspan="1">5&#x000b7;12</td><td rowspan="1" colspan="1">0&#x000b7;40</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;42</td><td rowspan="1" colspan="1">0&#x000b7;13</td><td rowspan="1" colspan="1">5&#x000b7;46</td><td rowspan="1" colspan="1">0&#x000b7;44</td><td rowspan="1" colspan="1">5&#x000b7;00</td><td rowspan="1" colspan="1">0&#x000b7;45</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;46</td><td rowspan="1" colspan="1">0&#x000b7;10</td><td rowspan="1" colspan="1">0&#x000b7;79</td></tr><tr><td rowspan="1" colspan="1">Inflammatory and CVD markers</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">MCP-1 (pg/ml)*</td><td align="left" rowspan="1" colspan="1">672</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">685</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">597</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">651</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">0&#x000b7;17</td></tr><tr><td rowspan="1" colspan="1">TNF-&#x003b1; (pg/ml)*</td><td rowspan="1" colspan="1">6&#x000b7;83</td><td rowspan="1" colspan="1">1&#x000b7;41</td><td rowspan="1" colspan="1">5&#x000b7;88</td><td rowspan="1" colspan="1">0&#x000b7;71</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;96</td><td rowspan="1" colspan="1">0&#x000b7;88</td><td rowspan="1" colspan="1">4&#x000b7;92</td><td rowspan="1" colspan="1">0&#x000b7;50</td><td rowspan="1" colspan="1">5&#x000b7;34</td><td rowspan="1" colspan="1">0&#x000b7;49</td><td rowspan="1" colspan="1">0&#x000b7;42</td><td rowspan="1" colspan="1">0&#x000b7;45</td><td rowspan="1" colspan="1">0&#x000b7;23</td></tr><tr><td rowspan="1" colspan="1">hsCRP (mg/l)*</td><td rowspan="1" colspan="1">1&#x000b7;64</td><td rowspan="1" colspan="1">0&#x000b7;36</td><td rowspan="1" colspan="1">1&#x000b7;65</td><td rowspan="1" colspan="1">0&#x000b7;43</td><td rowspan="1" colspan="1">0&#x000b7;00</td><td rowspan="1" colspan="1">0&#x000b7;21</td><td rowspan="1" colspan="1">1&#x000b7;78</td><td rowspan="1" colspan="1">0&#x000b7;35</td><td rowspan="1" colspan="1">1&#x000b7;74</td><td rowspan="1" colspan="1">0&#x000b7;54</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;04</td><td rowspan="1" colspan="1">0&#x000b7;31</td><td rowspan="1" colspan="1">0&#x000b7;81</td></tr><tr><td rowspan="1" colspan="1">IL-1ra (pg/ml)</td><td rowspan="1" colspan="1">116</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">115</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">&#x02212;1</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">114</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">&#x02212;6</td><td align="left" rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0&#x000b7;65</td></tr><tr><td rowspan="1" colspan="1">IL-6 (pg/ml)</td><td rowspan="1" colspan="1">123&#x000b7;6</td><td rowspan="1" colspan="1">39&#x000b7;7</td><td rowspan="1" colspan="1">86&#x000b7;8</td><td rowspan="1" colspan="1">28&#x000b7;7</td><td rowspan="1" colspan="1">&#x02212;36&#x000b7;8</td><td rowspan="1" colspan="1">39&#x000b7;0</td><td rowspan="1" colspan="1">105&#x000b7;9</td><td rowspan="1" colspan="1">30&#x000b7;8</td><td rowspan="1" colspan="1">63&#x000b7;0</td><td rowspan="1" colspan="1">25&#x000b7;5</td><td rowspan="1" colspan="1">&#x02212;42&#x000b7;9</td><td rowspan="1" colspan="1">31&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;99</td></tr><tr><td rowspan="1" colspan="1">PAI-1 (ng/ml)</td><td rowspan="1" colspan="1">2&#x000b7;49</td><td rowspan="1" colspan="1">0&#x000b7;45</td><td rowspan="1" colspan="1">3&#x000b7;69</td><td rowspan="1" colspan="1">0&#x000b7;74</td><td rowspan="1" colspan="1">1&#x000b7;20</td><td rowspan="1" colspan="1">0&#x000b7;65</td><td rowspan="1" colspan="1">1&#x000b7;96</td><td rowspan="1" colspan="1">0&#x000b7;47</td><td rowspan="1" colspan="1">3&#x000b7;41</td><td rowspan="1" colspan="1">0&#x000b7;54</td><td rowspan="1" colspan="1">1&#x000b7;45</td><td rowspan="1" colspan="1">0&#x000b7;37</td><td rowspan="1" colspan="1">0&#x000b7;76</td></tr><tr><td rowspan="1" colspan="1">Adiponectin (&#x003bc;g/ml)</td><td rowspan="1" colspan="1">14&#x000b7;1</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">14&#x000b7;7</td><td rowspan="1" colspan="1">1&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;56</td><td rowspan="1" colspan="1">0&#x000b7;73</td><td rowspan="1" colspan="1">14&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">14&#x000b7;2</td><td rowspan="1" colspan="1">1&#x000b7;57</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;06</td><td rowspan="1" colspan="1">0&#x000b7;51</td><td rowspan="1" colspan="1">0&#x000b7;42</td></tr><tr><td rowspan="1" colspan="1">Homocysteine (&#x003bc;mol/l)</td><td rowspan="1" colspan="1">10&#x000b7;24</td><td rowspan="1" colspan="1">0&#x000b7;45</td><td rowspan="1" colspan="1">9&#x000b7;69</td><td rowspan="1" colspan="1">0&#x000b7;46</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;55</td><td rowspan="1" colspan="1">0&#x000b7;39</td><td rowspan="1" colspan="1">9&#x000b7;57</td><td rowspan="1" colspan="1">0&#x000b7;58</td><td rowspan="1" colspan="1">9&#x000b7;93</td><td rowspan="1" colspan="1">0&#x000b7;43</td><td rowspan="1" colspan="1">0&#x000b7;36</td><td rowspan="1" colspan="1">0&#x000b7;46</td><td rowspan="1" colspan="1">0&#x000b7;12</td></tr><tr><td rowspan="1" colspan="1">Leptin (ng/ml)</td><td rowspan="1" colspan="1">16&#x000b7;2</td><td rowspan="1" colspan="1">2&#x000b7;7</td><td rowspan="1" colspan="1">14&#x000b7;8</td><td rowspan="1" colspan="1">2&#x000b7;5</td><td rowspan="1" colspan="1">&#x02212;1&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">17&#x000b7;7</td><td rowspan="1" colspan="1">3&#x000b7;7</td><td rowspan="1" colspan="1">15&#x000b7;9</td><td rowspan="1" colspan="1">2&#x000b7;7</td><td rowspan="1" colspan="1">&#x02212;1&#x000b7;8</td><td rowspan="1" colspan="1">2&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;79</td></tr><tr><td rowspan="1" colspan="1">Cystatin C (mg/l)</td><td rowspan="1" colspan="1">0&#x000b7;76</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">0&#x000b7;73</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;03</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;73</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">0&#x000b7;71</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;02</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">0&#x000b7;62</td></tr><tr><td rowspan="1" colspan="1">Resistin (ng/ml)</td><td rowspan="1" colspan="1">25&#x000b7;5</td><td rowspan="1" colspan="1">2&#x000b7;5</td><td rowspan="1" colspan="1">37&#x000b7;2</td><td rowspan="1" colspan="1">4&#x000b7;6</td><td rowspan="1" colspan="1">11&#x000b7;8</td><td rowspan="1" colspan="1">3&#x000b7;0</td><td rowspan="1" colspan="1">26&#x000b7;5</td><td rowspan="1" colspan="1">2&#x000b7;6</td><td rowspan="1" colspan="1">33&#x000b7;7</td><td rowspan="1" colspan="1">4&#x000b7;10</td><td rowspan="1" colspan="1">7&#x000b7;2</td><td rowspan="1" colspan="1">3&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;32</td></tr><tr><td rowspan="1" colspan="1">Serum amyloid A (&#x003bc;g/ml)</td><td rowspan="1" colspan="1">84&#x000b7;6</td><td rowspan="1" colspan="1">37&#x000b7;3</td><td rowspan="1" colspan="1">50&#x000b7;3</td><td rowspan="1" colspan="1">6&#x000b7;5</td><td rowspan="1" colspan="1">&#x02212;34&#x000b7;3</td><td rowspan="1" colspan="1">37&#x000b7;1</td><td rowspan="1" colspan="1">113&#x000b7;9</td><td rowspan="1" colspan="1">60&#x000b7;7</td><td rowspan="1" colspan="1">65&#x000b7;3</td><td rowspan="1" colspan="1">11&#x000b7;0</td><td rowspan="1" colspan="1">&#x02212;48&#x000b7;6</td><td rowspan="1" colspan="1">62&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;35</td></tr><tr><td rowspan="1" colspan="1">Myeloperoxidase (pg/ml)</td><td rowspan="1" colspan="1">40&#x000b7;8</td><td rowspan="1" colspan="1">11&#x000b7;6</td><td rowspan="1" colspan="1">79&#x000b7;1</td><td rowspan="1" colspan="1">29&#x000b7;4</td><td rowspan="1" colspan="1">38&#x000b7;3</td><td rowspan="1" colspan="1">19<sup>&#x000b7;</sup>4</td><td rowspan="1" colspan="1">43&#x000b7;0</td><td rowspan="1" colspan="1">9&#x000b7;0</td><td rowspan="1" colspan="1">65&#x000b7;5</td><td rowspan="1" colspan="1">15&#x000b7;9</td><td rowspan="1" colspan="1">22&#x000b7;5</td><td rowspan="1" colspan="1">15&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;42</td></tr><tr><td rowspan="1" colspan="1">ADMA* (&#x003bc;g/l)</td><td rowspan="1" colspan="1">86&#x000b7;5</td><td rowspan="1" colspan="1">2&#x000b7;6</td><td rowspan="1" colspan="1">112&#x000b7;2</td><td rowspan="1" colspan="1">14&#x000b7;8</td><td rowspan="1" colspan="1">25&#x000b7;7</td><td rowspan="1" colspan="1">14&#x000b7;4</td><td rowspan="1" colspan="1">82&#x000b7;9</td><td rowspan="1" colspan="1">4&#x000b7;4</td><td rowspan="1" colspan="1">98&#x000b7;9</td><td rowspan="1" colspan="1">10&#x000b7;8</td><td rowspan="1" colspan="1">15&#x000b7;9</td><td rowspan="1" colspan="1">11&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;47</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>MCP-1, monocyte chemotactic protein-1; hsCRP, highly sensitive C-reactive
protein; IL-1ra, IL-1 receptor antagonist; PAI-1, plasminogen activator inhibitor
1; ADMA, asymmetric dimethylarginine.</p></fn><fn id="tab-fn08"><label>*</label><p><italic>n</italic> 14 for ADMA, MCP-1 and TNF-&#x003b1;, <italic>n</italic> 13 for
hsCRP.</p></fn><fn><p>&#x02020; <italic>P</italic> values refer to comparisons between changes induced by the
<italic>n</italic>-3 PUFA and <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG treatments (ANOVA
for crossover design with two periods).</p></fn></table-wrap-foot></table-wrap></p><p>Changes in concentrations of inflammatory and CVD markers were not different between the
two treatments (<xref ref-type="table" rid="tab04">Table 4</xref>). However, a
sex&#x02013;treatment interaction was also observed for serum hsCRP concentrations
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;001). In males, <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG reduced serum hsCRP
by 40&#x000a0;% (1&#x000b7;23 (<sc>sem</sc> 0&#x000b7;25)&#x02013;0&#x000b7;74 (<sc>sem</sc> 0&#x000b7;18)&#x000a0;mg/l) whereas
<italic>n</italic>-3 PUFA increased hsCRP by 13&#x000a0;% (0&#x000b7;89 (<sc>sem</sc> 0&#x000b7;16)&#x02013;1&#x000b7;01
(<sc>sem</sc> 0&#x000b7;20)&#x000a0;mg/l) (<xref ref-type="fig" rid="fig02">Fig. 2(a)</xref>), provoking a
difference in hsCRP changes between <italic>n</italic>-3 PUFA and <italic>n</italic>-3
PUFA&#x000a0;+&#x000a0;FG (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;03). In females, <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG
increased serum hsCRP by 20&#x000a0;% (2&#x000b7;43 (<sc>sem</sc> 0&#x000b7;63)&#x02013;2&#x000b7;91 (<sc>sem</sc> 0&#x000b7;97)&#x000a0;mg/l)
whereas the <italic>n</italic>-3 PUFA supplement induced a 6&#x000a0;% reduction only (2&#x000b7;53
(<sc>sem</sc> 0&#x000b7;57)&#x02013;2&#x000b7;39 (<sc>sem</sc> 0&#x000b7;84)&#x000a0;mg/l) (<xref ref-type="fig" rid="fig02">Fig. 2(b)</xref>). There was thus no difference between hsCRP changes induced by the
two treatments in females (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;69). In the present study, there was a
sex&#x02013;treatment interaction on monocyte chemotactic protein-1 (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;04)
but because it was attributed to two hyper-responders to the <italic>n</italic>-3 PUFA
supplement, it does not seem to be of biological relevance in this study. <fig id="fig02" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Plasma highly sensitive C-reactive protein (hsCRP) concentrations before (pre) and
after (post) consuming <italic>n</italic>-3 PUFA and <italic>n</italic>-3
PUFA&#x000a0;+&#x000a0;fish gelatine (FG) (a) in males and (b) in females for 8 weeks. Values are
means, with standard errors represented by vertical bars, <italic>n</italic> 7 for
males, and <italic>n</italic> 6 for females. <italic>P</italic> value for
sex&#x02013;treatment interaction is 0&#x000b7;001. <italic>P</italic> value is 0&#x000b7;03 between changes
induced by the <italic>n</italic>-3 PUFA and <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG
supplements in males (ANOVA for crossover design with two experimental periods).</p></caption><graphic xlink:href="S2048679012000134_fig2"/></fig></p></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>The present free-living study investigated the effects of 8-week interventions with
<italic>n</italic>-3 PUFA and FG on lipid profile and inflammatory and CVD markers in
males and females with insulin resistance, a population with a known risk for CVD. The
marine <italic>n</italic>-3 PUFA supplement was used as the control. The main findings of
the study are that FG may enhance the lipid-lowering effect of fish <italic>n</italic>-3
PUFA in females and counteract the effect of <italic>n</italic>-3 PUFA on plasma hsCRP in
males. The concept that <italic>n</italic>-3 PUFA and fish protein could induce combined
reducing effects on TAG levels has emerged from an animal study<sup>(</sup><xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref><sup>)</sup>, but few studies have examined these effects on blood lipid profile in
human subjects. Because it has been shown that plasma TAG is one of the strongest predictors
for the risk of atherosclerosis and cardiovascular events in subjects with and without CVD,
this marker was chosen as the primary endpoint in the present study. Note that our study had
<italic>a posteriori</italic> power of 70&#x02013;80&#x000a0;% to detect a 20&#x000a0;% decrease in plasma TAG
concentrations. This percentage decrease was considered relevant because optimisation of
nutrition-related practices recommended by the American Heart Association can result in a
marked TAG-lowering effect that ranges between 20 and 50&#x000a0;%<sup>(</sup><xref rid="ref35" ref-type="bibr">
<sup>35</sup>
</xref><sup>)</sup>.</p><p>Fish oil consumption has well-documented and potent TAG-lowering effects<sup>(</sup><xref rid="ref2" ref-type="bibr">
<sup>2</sup>
</xref><sup>)</sup>. A comparable dose of <italic>n</italic>-3 PUFA to the one used in the
present study (1&#x000b7;8&#x000a0;g/d) has been shown to reduce plasma fasting TAG by approximately 20&#x000a0;%
(28-d intervention)<sup>(</sup><xref rid="ref37" ref-type="bibr">
<sup>37</sup>
</xref><sup>)</sup>. In the present study, an average 17&#x000a0;% decrease in plasma TAG was
observed in response to the <italic>n</italic>-3 PUFA treatment in our fifteen subjects. In
males, the <italic>n</italic>-3 PUFA supplementation decreased TAG concentrations by 25&#x000a0;%,
whereas in females, it decreased TAG by only 8&#x000a0;%. These results are in good agreement with
those of the FINGEN Study<sup>(</sup><xref rid="ref38" ref-type="bibr">
<sup>38</sup>
</xref><sup>)</sup>, showing a sex-treatment interaction in 312 adults aged 20&#x02013;70 years
consuming a moderate EPA/DHA (1&#x000b7;8&#x000a0;g EPA&#x02013;DHA/d) in a double-blind placebo-controlled
crossover study for an 8-week intervention period. As in the present study, the FINGEN Study
indicated a greater TAG-lowering action of <italic>n</italic>-3 PUFA in males than in
females.</p><p>It is well accepted that dietary protein intake contributes more strongly than carbohydrate
or fat intake to short-term satiety which, in turn, can have reducing effects on energy
intake, body weight and plasma lipids, although data in human subjects are still
inconclusive<sup>(</sup><xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref><sup>,</sup><xref rid="ref9" ref-type="bibr">
<sup>9</sup>
</xref><sup>)</sup>. In this study, an increase in consumed energy from protein and a
decrease in energy intake from carbohydrate in both males and females were observed with FG
supplementation without a change in the total energy intake, body weight, BMI and waist
circumference. No changes were observed in fibre intake, a nutrient known to affect satiety
and energy intake<sup>(</sup><xref rid="ref39" ref-type="bibr">
<sup>39</sup>
</xref><sup>)</sup>. There is thus a possibility that the effect upon satiety and energy
adjustment of dietary protein in liquid form may evoke weaker satiety signals than in the
solid form because of more rapid stomach emptying and transit of fluids through the
digestive tract<sup>(</sup><xref rid="ref40" ref-type="bibr">
<sup>40</sup>
</xref><sup>)</sup>.</p><p>Wolfe &#x00026; Piche<sup>(</sup><xref rid="ref41" ref-type="bibr">
<sup>41</sup>
</xref><sup>)</sup> and Wolfe &#x00026; Giovannetti<sup>(</sup><xref rid="ref42" ref-type="bibr">
<sup>42</sup>
</xref><sup>)</sup> have reported that the replacement of dietary carbohydrate by protein
could lower plasma TAG, but in the present study, the reducing effect of this substitution
on TAG was observed in females only. The present results thus indicate that the consumption
of <italic>n</italic>-3 PUFA with or without FG reduced plasma TAG, and the magnitude of
response depended on the treatment and on sex. Indeed in the present study, females had
significantly lower plasma TAG following <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG (&#x02212;23&#x000a0;%) than
<italic>n</italic>-3 PUFA (&#x02212;8&#x000a0;%) (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;04). By contrast, males had a
more pronounced plasma TAG reduction following <italic>n</italic>-3 PUFA (&#x02212;25&#x000a0;%) than
<italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG (&#x02212;11&#x000a0;%), albeit without reaching the level of significance.
The higher variability of TAG changes and the low number of subjects could explain the
absence of significant differences between the two treatments in males. According to
Hokanson &#x00026; Austin<sup>(</sup><xref rid="ref43" ref-type="bibr">
<sup>43</sup>
</xref><sup>)</sup>, reductions in moderately elevated TAG levels decrease cardiovascular
risk more in females than in males. Nevertheless, the marked TAG-lowering response either to
<italic>n</italic>-3 PUFA in males or to <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG in females was in
good agreement with the 20&#x02013;50&#x000a0;% TAG reduction expected from American Heart Association
nutritional recommendations<sup>(</sup><xref rid="ref35" ref-type="bibr">
<sup>35</sup>
</xref><sup>)</sup>. These results suggest that <italic>n</italic>-3 PUFA in males and
<italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG in females can be effective in helping to reduce plasma
TAG.</p><p>The TAG-lowering response to FG in females and not in males is consistent with the results
of previous human studies showing a decreasing effect of lean white fish diet on TAG
metabolism in pre-menopausal<sup>(</sup><xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref><sup>)</sup> and post-menopausal females<sup>(</sup><xref rid="ref13" ref-type="bibr">
<sup>13</sup>
</xref><sup>)</sup>, but not in normolipidaemic males<sup>(</sup><xref rid="ref14" ref-type="bibr">
<sup>14</sup>
</xref><sup>)</sup>. The observed TAG sex-dependent response in the present study could be
associated with an increase of sex hormone-binding globulin following the consumption of
fish protein in post-menopausal females<sup>(</sup><xref rid="ref13" ref-type="bibr">
<sup>13</sup>
</xref><sup>)</sup>. Increased testosterone and decreased sex hormone-binding globulin have
been linked to adverse cardiovascular risk factors, such as adiposity, increased TAG and
decreased HDL levels in both pre-menopausal and post-menopausal females<sup>(</sup><xref rid="ref44" ref-type="bibr">
<sup>44</sup>
</xref><sup>)</sup>. Furthermore, lower sex hormone-binding globulin levels predict
non-insulin-dependent diabetes mellitus in females but not in males<sup>(</sup><xref rid="ref45" ref-type="bibr">
<sup>45</sup>
</xref><sup>)</sup>. Additionally, a previous study conducted in our laboratory demonstrated
that fish protein can reduce insulin resistance<sup>(</sup><xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref><sup>)</sup>. Thus, the present results suggest that the divergent effects of FG
supplementation on plasma TAG between males and females may be mediated by variations in the
status of plasma sex hormones, which are related to glucose tolerance and insulin
sensitivity. Further studies on the mechanisms involved in the hypotriacylglycerolaemic
effects of FG in females are needed.</p><p>FG <italic>per se</italic> could also have modulated plasma TAG levels in the present
study. Our data are in line with those of Saito <italic>et al.</italic><sup>(</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>)</sup> who reported a decrease in plasma TAG concentrations in rats fed
hydrolysates of skin collagen. They observed that TAG levels were inversely correlated with
plasma total hydroxyproline, total glycine and total proline concentrations, three major
amino acids derived from low-molecular-weight collagen fish peptides<sup>(</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>)</sup>. Hafidi <italic>et al.</italic><sup>(</sup><xref rid="ref46" ref-type="bibr">
<sup>46</sup>
</xref><sup>)</sup> and Ratnayake <italic>et al.</italic><sup>(</sup><xref rid="ref47" ref-type="bibr">
<sup>47</sup>
</xref><sup>)</sup> have also reported a decrease in TAG levels following a diet rich in
glycine in rats fed a high-sucrose diet, suggesting that glycine could have contributed to
the observed TAG-lowering effects following the consumption of the FG broth in this study.
The lower lysine:arginine ratio of fish protein and gelatine compared with casein may also
have been involved<sup>(</sup><xref rid="ref48" ref-type="bibr">
<sup>48</sup>
</xref><sup>)</sup>. Moreover based on studies on fish protein in rats<sup>(</sup><xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref><sup>)</sup> and rabbits<sup>(</sup><xref rid="ref49" ref-type="bibr">
<sup>49</sup>
</xref><sup>)</sup>, there is a possibility that FG <italic>per se</italic> may have
contributed to decrease plasma TAG by increasing lipoprotein lipase activity.</p><p>Apart from the primary endpoint, inflammatory and other CVD markers (hsCRP, TNF-&#x003b1;, Il-6,
adiponectin and others) were assessed. Our data showed a sex&#x02013;treatment interaction for hsCRP
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;001). In males, while <italic>n</italic>-3 PUFA increased plasma
hsCRP concentrations by 13&#x000a0;%, <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG reduced these levels by 40&#x000a0;%.
This reduction was considered to be of biological significance because, on average, the CVD
risk based on plasma C-reactive protein concentrations decreased from moderate to low risk
in males<sup>(</sup><xref rid="ref34" ref-type="bibr">
<sup>34</sup>
</xref><sup>)</sup>. The C-reactive protein-lowering effect of FG in males is consistent
with our previous observations showing that short-term consumption of cod protein compared
with other animal proteins led to a decrease in hsCRP in insulin-resistant subjects, mostly
males<sup>(</sup><xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref><sup>)</sup>. However, in the present study, the serum hsCRP concentration was
increased in females by 20&#x000a0;% following <italic>n</italic>-3 PUFA&#x000a0;+&#x000a0;FG and decreased by 6&#x000a0;%
following <italic>n</italic>-3 PUFA.</p><p>There is, however, one limitation that needs to be addressed regarding the present study.
This limitation concerns the absence of no intervention and FG treatments to clearly
highlight the effects of FG. Although it has already been shown that fish protein and fish
oil have independent and additive effects on plasma TAG in rats<sup>(</sup><xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref><sup>)</sup> and thus that <italic>n</italic>-3 PUFA supplement can be used as the
control group, firm conclusions in this respect cannot be drawn in the present human study.
Therefore, in this study, the findings cannot be generalised beyond the comparison between
the effects of marine <italic>n</italic>-3 PUFA and those of <italic>n</italic>-3 PUFA plus
FG.</p><p>In conclusion, our data showed that, in free-living conditions, FG supplementation and a
concomitant decrease in carbohydrate intake enhanced the lipid-lowering effect of
<italic>n</italic>-3 PUFA supplementation in insulin-resistant females, and beneficially
counteracted the effect of <italic>n</italic>-3 PUFA on plasma C-reactive protein in
insulin-resistant males. These results suggest that FG may exert a beneficial effect on CVD
risk by lipid-lowering and anti-inflammatory effects in free-living insulin-resistant
females and males, respectively. Further studies are needed to elucidate the physiological
mechanisms underlying the divergent effects of <italic>n</italic>-3 PUFA and FG on TAG and
hsCRP levels between males and females, and to identify specific bioactive peptides and
amino acids that contribute to these effects.</p></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This research was supported by a grant from The Advanced Foods and Materials Network. There
are no conflicts of interest in this research. Ocean Nutrition Canada provided marine
<italic>n</italic>-3 PUFA capsules, and Norland Products provided fish gelatine. The
authors thank Simon Pelletier, Patricia Pelletier, Marc Majaron, Marie-&#x000c9;lise Carbonneau and
Nadine Leblanc for technical and skilful assistance. As to the contribution of each author
to the manuscript, H. J. designed the experiment and discussed the experimental results with
all the other co-authors, supervised E. P. D. and J. B. and assisted E. P. D. in writing the
manuscript. S. J. W. helped in designing the experiment, was responsible for the medical
follow-up of the participants and discussed the experimental results. As graduate students,
E. P. D. and J. B. carried out the experiment under the supervision of H. J., S. J. W., J.
M. and C. L. and discussed the experimental results. As a research coordinator, J.M. helped
in designing the study and the experiment plan, supervised and advised E. P. D and J. B. on
recruitment and nutritional aspects of the experiment, and discussed the experimental
results. C. L. and A. M. helped E. P. D. to carry out measurements of inflammatory markers
and to interpret data during the experiment. As a doctoral student, E. C. supervised by J.
S. H. helped E. P. D. to carry out measurements of cardiovascular markers. E. C., J. S. H.
and J. F. discussed the experimental results and supervised E. P. D.'s training in their
laboratory. B. H. helped in designing the study and to interpret the data.</p></ack><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Schenk</surname><given-names>S</given-names></name>, <name><surname>Saberi</surname><given-names>M</given-names></name> &#x00026; <name><surname>Olefsky</surname><given-names>JM</given-names></name> (<year>2008</year>) <article-title>Insulin sensitivity: modulation by nutrients
and inflammation</article-title>. <source>J Clin Invest</source><volume>118</volume>, <fpage>2992</fpage>&#x02013;<lpage>3002</lpage><pub-id pub-id-type="pmid">18769626</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Harris</surname><given-names>WS</given-names></name>, <name><surname>Michael</surname><given-names>M</given-names></name>, <name><surname>Ann</surname><given-names>PT</given-names></name>, <etal/> (<year>2008</year>) <article-title>Omega-3 fatty acids and coronary heart
disease risk: clinical and mechanistic perspectives</article-title>.
<source>Atherosclerosis</source><volume>197</volume>, <fpage>12</fpage>&#x02013;<lpage>24</lpage><pub-id pub-id-type="pmid">18160071</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Calder</surname><given-names>PC</given-names></name> (<year>2006</year>) <article-title><italic>n</italic>-3 Polyunsaturated fatty
acids, inflammation, and inflammatory diseases</article-title>. <source>Am J Clin Nutr</source><volume>83</volume>, <fpage>1505S</fpage>&#x02013;<lpage>1519S</lpage><pub-id pub-id-type="pmid">16841861</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Schacky</surname><given-names>C</given-names></name> (<year>2007</year>) <article-title><italic>n</italic>-3 PUFA in CVD: influence of
cytokine polymorphism</article-title>. <source>Proc Nutr Soc</source><volume>66</volume>, <fpage>166</fpage>&#x02013;<lpage>170</lpage><pub-id pub-id-type="pmid">17466099</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Vega-Lopez</surname><given-names>S</given-names></name>, <name><surname>Kaul</surname><given-names>N</given-names></name>, <name><surname>Devaraj</surname><given-names>S</given-names></name>, <etal/> (<year>2004</year>) <article-title>Supplementation with omega-3
polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed
to exert an anti-inflammatory effect in human volunteers</article-title>.
<source>Metabolism</source><volume>53</volume>, <fpage>236</fpage>&#x02013;<lpage>240</lpage><pub-id pub-id-type="pmid">14767877</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Mori</surname><given-names>TA</given-names></name>, <name><surname>Woodman</surname><given-names>RJ</given-names></name>, <name><surname>Burke</surname><given-names>V</given-names></name>, <etal/> (<year>2003</year>) <article-title>Effect of eicosapentaenoic acid and
docosahexaenoic acid on oxidative stress and inflammatory markers in
treated-hypertensive type 2 diabetic subjects</article-title>. <source>Free Radical Biol
Med</source><volume>35</volume>, <fpage>772</fpage>&#x02013;<lpage>781</lpage><pub-id pub-id-type="pmid">14583341</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Klein</surname><given-names>S</given-names></name>, <name><surname>Sheard</surname><given-names>NF</given-names></name>, <name><surname>Pi-Sunyer</surname><given-names>X</given-names></name>, <etal/> (<year>2004</year>) <article-title>Weight management through lifestyle
modification for the prevention and management of type 2 diabetes: rationale and
strategies. A statement of the American Diabetes Association, the North American
Association for the Study of Obesity, and the American Society for Clinical
Nutrition</article-title>. <source>Am J Clin Nutr</source><volume>80</volume>, <fpage>257</fpage>&#x02013;<lpage>263</lpage><pub-id pub-id-type="pmid">15277143</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Westerterp-Plantenga</surname><given-names>MS</given-names></name>, <name><surname>Nieuwenhuizen</surname><given-names>A</given-names></name>, <name><surname>Tome</surname><given-names>D</given-names></name>, <etal/> (<year>2009</year>) <article-title>Dietary protein, weight loss, and
weight maintenance</article-title>. <source>Annu Rev Nutr</source><volume>29</volume>, <fpage>21</fpage>&#x02013;<lpage>41</lpage><pub-id pub-id-type="pmid">19400750</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Halton</surname><given-names>LT</given-names></name> &#x00026; <name><surname>Hu</surname><given-names>FB</given-names></name> (<year>2004</year>) <article-title>The effects of high protein diets on
thermogenesis, satiety and weight loss: a critical review</article-title>. <source>J Am
Coll Nutr</source><volume>23</volume>, <fpage>373</fpage>&#x02013;<lpage>385</lpage><pub-id pub-id-type="pmid">15466943</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Lavigne</surname><given-names>C</given-names></name>, <name><surname>Tremblay</surname><given-names>F</given-names></name>, <name><surname>Asselin</surname><given-names>G</given-names></name>, <etal/> (<year>2001</year>) <article-title>Prevention of skeletal muscle insulin
resistance by dietary cod protein in high fat-fed rats</article-title>. <source>Am J
Physiol Endocrinol Metab</source><volume>281</volume>, <fpage>E62</fpage>&#x02013;<lpage>E71</lpage><pub-id pub-id-type="pmid">11404223</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Ouellet</surname><given-names>V</given-names></name>, <name><surname>Marois</surname><given-names>J</given-names></name>, <name><surname>Weisnagel</surname><given-names>SJ</given-names></name>, <etal/> (<year>2007</year>) <article-title>Dietary cod protein improves insulin
sensitivity in insulin-resistant men and women</article-title>. <source>Diabetes Care</source><volume>30</volume>, <fpage>2816</fpage>&#x02013;<lpage>2821</lpage><pub-id pub-id-type="pmid">17682120</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Gascon</surname><given-names>A</given-names></name>, <name><surname>Jacques</surname><given-names>H</given-names></name>, <name><surname>Moorjani</surname><given-names>S</given-names></name>, <etal/> (<year>1996</year>) <article-title>Plasma lipoprotein profile and
lipolytic activities in response to the substitution of lean white fish for other animal
protein sources in premenopausal women</article-title>. <source>Am J Clin Nutr</source><volume>63</volume>, <fpage>315</fpage>&#x02013;<lpage>321</lpage><pub-id pub-id-type="pmid">8602586</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Jacques</surname><given-names>H</given-names></name>, <name><surname>Noreau</surname><given-names>L</given-names></name> &#x00026; <name><surname>Moorjani</surname><given-names>S</given-names></name> (<year>1992</year>) <article-title>Effects on plasma lipoproteins and endogenous
sex hormones of substituting lean white fish for other animal protein sources in diets
of postmenopausal women</article-title>. <source>Am J Clin Nutr</source><volume>55</volume>, <fpage>896</fpage>&#x02013;<lpage>901</lpage><pub-id pub-id-type="pmid">1550074</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Lacaille</surname><given-names>B</given-names></name>, <name><surname>Julien</surname><given-names>P</given-names></name>, <name><surname>Deshaies</surname><given-names>Y</given-names></name>, <etal/> (<year>2000</year>) <article-title>Responses of plasma lipoproteins and
sex hormones to the consumption of lean fish incorporated in a prudent-type diet in
normolipidemic men</article-title>. <source>J Am Coll Nutr</source><volume>19</volume>, <fpage>745</fpage>&#x02013;<lpage>753</lpage><pub-id pub-id-type="pmid">11194527</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Beauchesne-Rondeau</surname><given-names>E</given-names></name>, <name><surname>Gascon</surname><given-names>A</given-names></name>, <name><surname>Bergeron</surname><given-names>J</given-names></name>, <etal/> (<year>2003</year>) <article-title>Plasma lipids and lipoproteins in
hypercholesterolemic men fed a lipid-lowering diet containing lean beef, lean fish, or
poultry</article-title>. <source>Am J Clin Nutr</source><volume>77</volume>, <fpage>587</fpage>&#x02013;<lpage>593</lpage><pub-id pub-id-type="pmid">12600847</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Ouellet</surname><given-names>V</given-names></name>, <name><surname>Weisnagel</surname><given-names>J</given-names></name>, <name><surname>Marois</surname><given-names>J</given-names></name>, <etal/> (<year>2008</year>) <article-title>Dietary cod protein reduces plasma
C-reactive protein in insulin-resistant men and women</article-title>. <source>J Nutr</source><volume>138</volume>, <fpage>2386</fpage>&#x02013;<lpage>2391</lpage><pub-id pub-id-type="pmid">19022962</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Pot</surname><given-names>GK</given-names></name>, <name><surname>Geelen</surname><given-names>A</given-names></name> &#x00026; <name><surname>Majsak-Newman</surname><given-names>G</given-names></name> (<year>2010</year>) <article-title>Increased consumption of fatty and lean fish
reduces serum C-reactive protein concentrations but not inflammation markers in feces
and in colonic biopsies</article-title>. <source>J Nutr</source><volume>140</volume>, <fpage>371</fpage>&#x02013;<lpage>376</lpage><pub-id pub-id-type="pmid">20032491</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Demonty</surname><given-names>I</given-names></name>, <name><surname>Deshaies</surname><given-names>Y</given-names></name>, <name><surname>Lamarche</surname><given-names>B</given-names></name>, <etal/> (<year>2003</year>) <article-title>Cod protein lowers the hepatic
triglyceride secretion rate in rats</article-title>. <source>J Nutr</source><volume>133</volume>, <fpage>1398</fpage>&#x02013;<lpage>1402</lpage><pub-id pub-id-type="pmid">12730428</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Karim</surname><given-names>AA</given-names></name> &#x00026; <name><surname>Bhat</surname><given-names>R</given-names></name> (<year>2009</year>) <article-title>Fish gelatin: properties, challenges, and
prospects as an alternative to mammalian gelatins</article-title>. <source>Food
Hydrocolloids</source><volume>23</volume>, <fpage>563</fpage>&#x02013;<lpage>576</lpage></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Bello</surname><given-names>AE</given-names></name> &#x00026; <name><surname>Oesser</surname><given-names>S</given-names></name> (<year>2006</year>) <article-title>Collagen hydrolysate for the treatment of
osteoarthritis and other joint disorders: a review of the literature</article-title>.
<source>Curr Med Res Opin</source><volume>22</volume>, <fpage>2221</fpage>&#x02013;<lpage>2232</lpage><pub-id pub-id-type="pmid">17076983</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Saito</surname><given-names>M</given-names></name>, <name><surname>Kiyose</surname><given-names>C</given-names></name>, <name><surname>Higuchi</surname><given-names>T</given-names></name>, <etal/> (<year>2009</year>) <article-title>Effect of collagen hydrolysates from
salmon and trout skins on the lipid profile in rats</article-title>. <source>J Agric
Food Chem</source><volume>57</volume>, <fpage>10477</fpage>&#x02013;<lpage>10482</lpage><pub-id pub-id-type="pmid">19831419</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>J</given-names></name>, <name><surname>Fujioka</surname><given-names>M</given-names></name>, <name><surname>Sugimoto</surname><given-names>K</given-names></name><etal/> (<year>2004</year>) <article-title>Assessment of effectiveness of oral
administration of collagen peptides on bone metabolism in growing and mature
rats</article-title>. <source>J Bone Miner Metab</source><volume>22</volume>, <fpage>547</fpage>&#x02013;<lpage>553</lpage><pub-id pub-id-type="pmid">15490264</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Shi</surname><given-names>H</given-names></name> &#x00026; <name><surname>Clegg</surname><given-names>DJ</given-names></name> (<year>2009</year>) <article-title>Sex differences in the regulation of body
weight</article-title>. <source>Physiol Behav</source><volume>97</volume>, <fpage>199</fpage>&#x02013;<lpage>204</lpage><pub-id pub-id-type="pmid">19250944</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Pilote</surname><given-names>L</given-names></name>, <name><surname>Dasgupta</surname><given-names>K</given-names></name>, <name><surname>Guru</surname><given-names>V</given-names></name>, <etal/> (<year>2007</year>) <article-title>A comprehensive view of sex-specific
issues related to cardiovascular disease</article-title>. <source>Can Med Assoc J</source><volume>176</volume>, <fpage>S1</fpage>&#x02013;<lpage>S44</lpage><pub-id pub-id-type="pmid">17353516</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="book"><name><surname>Kahn</surname><given-names>SE</given-names></name>, <name><surname>McCulloch</surname><given-names>DK</given-names></name> &#x00026; <name><surname>Porte</surname><given-names>D</given-names></name> (<year>1997</year>) <chapter-title>Insulin secretion in the normal and diabetic
human</chapter-title> In <source>International Textbook of Diabetes Mellitus</source>,
<edition>2nd ed.</edition>, pp. <fpage>337</fpage>&#x02013;<lpage>354</lpage> [<string-name>
<given-names>KGMM</given-names>
<surname>Alberti</surname>
</string-name>, <string-name>
<given-names>P</given-names>
<surname>Zimmet</surname>
</string-name>, <string-name>
<given-names>RA</given-names>
<surname>Defronzo</surname>
</string-name> and <name><surname>H</surname><given-names>Keen</given-names></name>, editors]. <publisher-loc>New York</publisher-loc>: <publisher-name>John Wiley
&#x00026; Sons</publisher-name></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Scarsella</surname><given-names>C</given-names></name>, <name><surname>Almeras</surname><given-names>N</given-names></name>, <name><surname>Mauriege</surname><given-names>P</given-names></name>, <etal/> (<year>2000</year>) <article-title>Determination of reference values for
fasting insulin levels in a representative sample of the adult Quebec
population</article-title>. <source>Atherosclerosis</source><volume>151</volume>, 101.</mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><collab>American Diabetes
Association</collab> (<year>2010</year>) <article-title>Standards of medical care in
diabetes (position statement)</article-title>. <source>Diabetes Care</source><volume>33</volume>, <fpage>S11</fpage>&#x02013;<lpage>S61</lpage><pub-id pub-id-type="pmid">20042772</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Beaulieu</surname><given-names>L</given-names></name>, <name><surname>Thibodeau</surname><given-names>J</given-names></name>, <name><surname>Bryl</surname><given-names>P</given-names></name>, <etal/> (<year>2009</year>) <article-title>Proteolytic processing of Atlantic
mackerel (<italic>Scomber scombrus</italic>) and biochemical characterisation of
hydrolysates</article-title>. <source>Int J Food Sci Tech</source><volume>44</volume>, <fpage>1609</fpage>&#x02013;<lpage>1618</lpage></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Moorjani</surname><given-names>S</given-names></name>, <name><surname>Gagn&#x000e9;</surname><given-names>C</given-names></name>, <name><surname>Lupien</surname><given-names>PJ</given-names></name>, <etal/> (<year>1986</year>) <article-title>Plasma triglycerides related decrease
in high-density lipoprotein cholesterol and its association with myocardial infarction
in heterozygous familial hypercholesterolemia</article-title>. <source>Metabolism</source><volume>35</volume>, <fpage>311</fpage>&#x02013;<lpage>316</lpage><pub-id pub-id-type="pmid">3959903</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Burstein</surname><given-names>M</given-names></name> &#x00026; <name><surname>Samaille</surname><given-names>J</given-names></name> (<year>1960</year>) <article-title>Sur un dosage rapide du cholest&#x000e9;rol li&#x000e9; aux
B-lipoproteins du s&#x000e9;rum (On a rapid determination of cholesterol bound to serum alpha-
and beta-lipoproteins)</article-title>. <source>Clin Chim Acta</source><volume>5</volume>, <fpage>609</fpage>&#x02013;<lpage>610</lpage><pub-id pub-id-type="pmid">13806309</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="book"><name><surname>Conover</surname><given-names>WJ</given-names></name> (<year>1999</year>) <chapter-title>Some methods based on ranks</chapter-title> In
<source>Practical Nonparametric Statistics</source>, <edition>3rd ed.</edition>, pp.
<fpage>419</fpage>&#x02013;<lpage>420</lpage> [<string-name>
<given-names>B</given-names>
<surname>Wiley</surname>
<suffix>II</suffix>
</string-name>, <string-name>
<given-names>M</given-names>
<surname>O'Sullivan</surname>
</string-name> and <string-name>
<given-names>J</given-names>
<surname>Perea</surname>
</string-name>, editors]. <publisher-loc>New York</publisher-loc>: <publisher-name>John
Wiley &#x00026; Sons</publisher-name></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Alberti</surname><given-names>KG</given-names></name>, <name><surname>Zimmet</surname><given-names>P</given-names></name> &#x00026; <name><surname>Shaw</surname><given-names>J</given-names></name> (<year>2006</year>) <article-title>Metabolic syndrome &#x02013; a new world-wide
definition. A consensus statement from the International Diabetes
Federation</article-title>. <source>Diabet Med</source><volume>23</volume>, <fpage>469</fpage>&#x02013;<lpage>480</lpage><pub-id pub-id-type="pmid">16681555</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Grundy</surname><given-names>SM</given-names></name>, <name><surname>Bryan</surname><given-names>HB</given-names></name>, <name><surname>Cleeman</surname><given-names>JI</given-names></name>, <etal/> (<year>2004</year>) <article-title>Definition of metabolic syndrome
report of the National Heart, Lung, and Blood Institute/American Heart Association
conference on scientific issues related to definition</article-title>.
<source>Circulation</source><volume>109</volume>, <fpage>433</fpage>&#x02013;<lpage>438</lpage><pub-id pub-id-type="pmid">14744958</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Pearson</surname><given-names>TA</given-names></name>, <name><surname>Mensah</surname><given-names>GA</given-names></name>, <name><surname>Alexander</surname><given-names>RW</given-names></name>, <etal/> (<year>2003</year>) <article-title>Markers of inflammation and
cardiovascular disease: application to clinical and public health practice: a statement
for healthcare professionals from the Centers for Disease Control and Prevention and the
American Heart Association</article-title>. <source>Circulation</source><volume>107</volume>, <fpage>499</fpage>&#x02013;<lpage>511</lpage><pub-id pub-id-type="pmid">12551878</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>M</given-names></name>, <name><surname>Stone</surname><given-names>NJ</given-names></name>, <name><surname>Ballantyne</surname><given-names>C</given-names></name>, <etal/> (<year>2011</year>) <article-title>Triglycerides and cardiovascular
disease: a scientific statement from the American Heart Association</article-title>.
<source>Circulation</source><volume>123</volume>, <fpage>2292</fpage>&#x02013;<lpage>2333</lpage><pub-id pub-id-type="pmid">21502576</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><collab>National Cholesterol
Education Program</collab> (<year>2002</year>) <article-title>Third report of the
National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and
treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final
Report</article-title>. <source>Circulation</source><volume>106</volume>, <fpage>3143</fpage>&#x02013;<lpage>3421</lpage><pub-id pub-id-type="pmid">12485966</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Stark</surname><given-names>KD</given-names></name> &#x00026; <name><surname>Holub</surname><given-names>BJ</given-names></name> (<year>2004</year>) <article-title>Differential eicosapentaenoic acid elevations
and altered cardiovascular disease risk factor responses after supplementation with
docosahexaenoic acid in postmenopausal women receiving and not receiving hormone
replacement therapy</article-title>. <source>Am J Clin Nutr</source><volume>79</volume>, <fpage>765</fpage>&#x02013;<lpage>773</lpage><pub-id pub-id-type="pmid">15113713</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>Caslake</surname><given-names>MJ</given-names></name>, <name><surname>Miles</surname><given-names>EA</given-names></name>, <name><surname>Kofler</surname><given-names>BM</given-names></name>, <etal/> (<year>2008</year>) <article-title>Effect of sex and genotype on
cardiovascular biomarker response to fish oils: the FINGEN Study</article-title>.
<source>Am J Clin Nutr</source><volume>88</volume>, <fpage>618</fpage>&#x02013;<lpage>629</lpage><pub-id pub-id-type="pmid">18779276</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Burton-Freeman</surname><given-names>B</given-names></name> (<year>2000</year>) <article-title>Dietary fiber and energy
regulation</article-title>. <source>J Nutr</source><volume>130</volume>, <fpage>272S</fpage>&#x02013;<lpage>275S</lpage><pub-id pub-id-type="pmid">10721886</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><name><surname>DiMeglio</surname><given-names>DP</given-names></name> &#x00026; <name><surname>Mattes</surname><given-names>RD</given-names></name> (<year>2000</year>) <article-title>Liquid versus solid carbohydrate: effects on
food intake and body weight</article-title>. <source>Int J Obes</source><volume>24</volume>, <fpage>794</fpage>&#x02013;<lpage>800</lpage></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><name><surname>Wolfe</surname><given-names>BM</given-names></name> &#x00026; <name><surname>Piche</surname><given-names>LA</given-names></name> (<year>1999</year>) <article-title>Replacement of carbohydrate by protein in a
conventional-fat diet reduces cholesterol and triglyceride concentrations in healthy
normolipidemic subjects</article-title>. <source>Clin Invest Med</source><volume>22</volume>, <fpage>140</fpage>&#x02013;<lpage>148</lpage><pub-id pub-id-type="pmid">10497712</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><name><surname>Wolfe</surname><given-names>BM</given-names></name> &#x00026; <name><surname>Giovannetti</surname><given-names>PM</given-names></name> (<year>1991</year>) <article-title>Short-term effects of substituting protein for
carbohydrate in the diets of moderately hypercholesterolemic human
subjects</article-title>. <source>Metabolism</source><volume>40</volume>, <fpage>338</fpage>&#x02013;<lpage>343</lpage><pub-id pub-id-type="pmid">2011075</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><name><surname>Hokanson</surname><given-names>JE</given-names></name> &#x00026; <name><surname>Austin</surname><given-names>MA</given-names></name> (<year>1996</year>) <article-title>Plasma triglyceride level is a risk factor for
cardiovascular disease independent of high-density lipoprotein cholesterol level: a
meta-analysis of population-based prospective studies</article-title>. <source>J
Cardiovasc Risk</source><volume>3</volume>, <fpage>213</fpage>&#x02013;<lpage>219</lpage><pub-id pub-id-type="pmid">8836866</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><name><surname>Pugeat</surname><given-names>M</given-names></name>, <name><surname>Moulin</surname><given-names>P</given-names></name>, <name><surname>Cousin</surname><given-names>P</given-names></name>, <etal/> (<year>1995</year>) <article-title>Interrelations between sex
hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular
risk</article-title>. <source>J Steroid Biochem Mol Biol</source><volume>53</volume>, <fpage>567</fpage>&#x02013;<lpage>572</lpage><pub-id pub-id-type="pmid">7626511</pub-id></mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><name><surname>Haffner</surname><given-names>SM</given-names></name>, <name><surname>Valdez</surname><given-names>RA</given-names></name>, <name><surname>Morales</surname><given-names>PA</given-names></name>, <etal/> (<year>1993</year>) <article-title>Decreased sex hormone-binding globulin
predicts noninsulin-dependent diabetes mellitus in women but not in men</article-title>.
<source>J Clin Endocrinol Metab</source><volume>77</volume>, <fpage>56</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="pmid">8325960</pub-id></mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><name><surname>Hafidi</surname><given-names>M</given-names></name>, <name><surname>Perez</surname><given-names>I</given-names></name>, <name><surname>Zamora</surname><given-names>J</given-names></name>, <etal/> (<year>2004</year>) <article-title>Glycine intake decreases plasma free
fatty acids, adipose cell size, and blood pressure in sucrose-fed rats</article-title>.
<source>Am J Physiol Regul Integr Comp Physiol</source><volume>287</volume>, <fpage>R1387</fpage>&#x02013;<lpage>R1393</lpage><pub-id pub-id-type="pmid">15331379</pub-id></mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><name><surname>Ratnayake</surname><given-names>N</given-names></name>, <name><surname>Sarwar</surname><given-names>G</given-names></name> &#x00026; <name><surname>Laffey</surname><given-names>P</given-names></name> (<year>1997</year>) <article-title>Influence of dietary protein and fat on serum
lipids and metabolism of essential fatty acids in rats</article-title>. <source>Br J
Nutr</source><volume>78</volume>, <fpage>459</fpage>&#x02013;<lpage>467</lpage><pub-id pub-id-type="pmid">9306886</pub-id></mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><name><surname>Pfeuffer</surname><given-names>M</given-names></name> &#x00026; <name><surname>Barth</surname><given-names>CA</given-names></name> (<year>1992</year>) <article-title>Dietary sucrose but not starch promotes
protein-induced differences in rates of VLDL secretion and plasma lipid concentrations
in rats</article-title>. <source>J Nutr</source><volume>122</volume>, <fpage>1582</fpage>&#x02013;<lpage>1586</lpage><pub-id pub-id-type="pmid">1619483</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><name><surname>Bergeron</surname><given-names>N</given-names></name>, <name><surname>Deshaies</surname><given-names>Y</given-names></name> &#x00026; <name><surname>Jacques</surname><given-names>H</given-names></name> (<year>1992</year>) <article-title>Dietary fish protein modulates high density
lipoprotein cholesterol and lipoprotein lipase activity in rabbits</article-title>.
<source>J Nutr</source><volume>122</volume>, <fpage>1731</fpage>&#x02013;<lpage>1737</lpage><pub-id pub-id-type="pmid">1640268</pub-id></mixed-citation></ref></ref-list></back></article>